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 The peroxidation of polyunsaturated fatty acids is a hallmark of many human disorders, 
yet is has often remained ambiguous whether lipid peroxidation plays a causative and therefore 
addressable role in the onset or pathogenesis of a disease. Small molecule inhibitors of this 
oxidative process in theory possess the capacity to help clarify this ambiguity, but many of the 
currently available compounds have important limitations. We therefore proposed that context-
specific selective pressures may have promoted the evolution of natural products with potent 
antilipoperoxidant activity in microorganisms that thrive in environments of extreme oxidative 
stress. Enabled by a modular building-block synthetic platform, the structurally atypical 
carotenoid peridinin was found to be a potent inhibitor of non-enzymatic bilayer lipid 
peroxidation.   
 With the goal of maximizing the utility of peridinin as a small molecule probe of the role 
of lipid peroxidation in pathogenesis, the mechanistic underpinnings of its antilipoperoxidant 
activity were investigated. Solid-state NMR experiments with a site-selectively 13C-labeled 
peridinin isotopologue revealed that the potency is linked to a high effective molarity within lipid 
bilayers. In contrast to the primarily extramembranous localization of the less effective 
antilipoperoxidant astaxanthin, peridinin is completely embedded within and physically spans 
the hydrophobic core of lipid membranes.  
This antilipoperoxidant probe was leveraged in human primary endothelial cell and 
mouse model experiments to interrogate the contribution of membrane oxidation towards the 
pathogenesis of atherosclerosis and asthma. The peridinin-mediated mitigation of bilayer lipid 
peroxidation was shown to attenuate monocyte-endothelial cell adhesion, a key step in 
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atherogenesis. Utilizing mouse models of acute asthma, we found that lipid peroxidation is 
alternatively not a key driver of the asthmatic phenotype. These results suggest that peridinin 
may have broad potential as a chemical probe to better understand the role of bilayer lipid 
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Lipids are a critical component of cellular membranes, which function to structurally 
organize and protect cells.1 Many lipid species, however, are susceptible to modification by 
reactive oxygen species (ROS), such as those derived from the reduction of molecular oxygen.2 
Specifically, polyunsaturated fatty acids (PUFAs) including arachidonic acid and linoleic acid 
contain bisallylic C-H bonds (L-H) which possess relatively low bond dissociation energies and 
therefore undergo radical abstraction to generate the corresponding delocalized carbon radicals 
(Figure 1-1).3 This represents the initiating step in the free radical chain peroxidation of 
polyunsaturated lipids. Subsequent addition of molecular oxygen to the carbon radical generates 
the lipid peroxyl radical (LOO!), a chain-carrying species in this mechanism. The lipid peroxyl 
radical can either abstract a bisallylic C-H from a second unsaturated lipid to propagate lipid 
peroxidation, or react with another peroxyl radical in a termination step. Importantly, the lipid 
peroxyl radical can also be scavenged by a radical trapping antilipoperoxidant to inhibit the 
oxidative process. Although enzymatic lipid peroxidation can play important physiologic 
functions, rampant free radical lipid peroxidation is deleterious.4-6 This process can impair the 
structural integrity of lipid bilayers, and oxidized lipid products can both covalently modify 





1-1 THE ROLE OF LIPID PEROXIDATION IN HUMAN PATHOPHYSIOLOGY 
The peroxidation of polyunsaturated fatty acids is a hallmark of many human 
pathophysiologies, including atherosclerosis,7, 8 ischemia/reperfusion injury,9 diabetes,10 and 
asthma.11 It has often remained ambiguous, however, whether lipid peroxidation plays a 
causative role in the onset and/or progression of a disease or rather is simply correlative. 
Evidence for a causative contribution in several pathophysiologies has been provided by 
epidemiological studies. Loss-of-function mutations in proteins that mitigate the peroxidation of 
bilayer lipids and/or eliminate its products, such as glutathione-S-transferase (GST) and 
glutathione peroxidase (GPX), have been associated with increased incidence or severity of 
atherosclerosis snd several other important human diseases.12-15 GPX enzymes have been 
identified as particularly important because they directly detoxify lipid hydroperoxides via 
reduction and thus maintain a low concentration of lipid peroxidation products.16
 
GPX-1 activity 
has been inversely correlated with risk for coronary artery disease and cardiovascular events, the 
extent of atherosclerosis throughout the major vascular beds, and carotid artery intima-media 
thickness, a clinically relevant marker of atherosclerosis.13, 14, 16-18 A protective role for GPX-1 in 
atherogenesis has also been observed in mouse models in which GPX-1-/- knock-out mice 
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Figure 1-1. (a) Structures of common polyunsaturated lipid species. (b) Mechanism of lipid 
peroxidation. L-H indicates a bisallylic C-H bond.        
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and macrophage infiltration within the arterial wall.19-23  
These studies support a critical role for lipid oxidation in atherosclerosis, which is 
consistent with an increasingly well-characterized mechanism in which specific oxidized lipid 
species bind to cellular receptors, thus initiating atherogenesis.24 The current model describes 
two distinct pathways by which lipid oxidation is proposed to contribute to the onset of the 
disease (Figure 1-2).  
 
 
In the first pathway, a role for lipids found within low-density lipoprotein (LDL) particles 
localized in the arterial subendothelial space is outlined (Figure 1-2, left).25 The oxidation of 
polyunsaturated phospholipids generates a range of bioactive derivatives, including 1-palmitoyl-
2-glutaryl-sn-glycero-3-phosphocholine (PGPC), 1-palmitoyl-2-(5’-oxo-valeroyl)-sn-glycero-3-
phosphocholine (POVPC), and 1-palmitoyl-2-(5,6)-epoxyisoprostane E2-sn-glycero-3-
phosphocholine (PEIPC), which bind to endothelial receptors such as the prostaglandin E2 
receptor (Figure 1-3).26, 27 This recognition event activates proatherogenic endothelial signaling 














Figure 1-2. Lipid peroxidation is proposed to contribute to the onset of atherogenesis via two distinct 
pathways.          
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and inflammatory pathways, resulting in the upregulation of leukocyte binding molecules and 
chemokines such as monocyte chemoattractant protein 1 (MCP-1) and vascular cell adhesion 
molecule 1 (VCAM-1).8 Ultimately, the expression of monocyte binding molecules and 
chemotactic factors mediate monocyte movement into the subendothelial space, differentiation 
into macrophages and formation of necrotic or apoptotic foam cells, which are key constituents 
of atherosclerotic plaques.8  
 
 
The second pathway highlights the role of endogenous PUFAs in plasma membranes of 
the arterial endothelium towards promotion of the same initiating monocyte-binding event in 
atherogenesis (Figure 1-2, right).7 In this “lipid whisker model,” the oxidation of bilayer fatty 
acyl tails promotes flipping from the hydrophobic core of the lipid membrane to the bilayer 
surface, where they function as exposed ligands for scavenger receptors on circulating 
monocytes, such as the CD36 receptor.28 This recognition event results in monocyte adhesion 


























Figure 1-3. The non-enzymatic oxidation of PAPC can result in the formation of bioactive 
phospholipids including PGPC, POVPC, and PEIPC.            
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The clinical success of the statins towards the concomitant reduction in both circulating 
LDL levels and the risk of major coronary events in patients has provided significant evidence 
for the importance of the first pathway in atherogenesis.29, 30 Statins specifically inhibit 
cholesterol biosynthesis, resulting in reduced concentrations in the liver which elicits increased 
expression of hepatic LDL receptors, and therefore a decrease in circulating LDL levels. This 
strategy ultimately relies on reducing the available concentration of the oxidizable LDL substrate 
rather than the direct inhibition of lipid peroxidation in the particles.  
Implementation of the analogous strategy in the context of the lipid whisker model is not 
possible because the substrate is the cellular bilayer itself. Clinical trials targeting this process 
have therefore implemented small molecules thought to inhibit membrane lipid peroxidation, 
including vitamin E, β-carotene, and astaxanthin, yet the results have largely indicated no 
positive effect of supplementation towards the reduction of cardiovascular events (Figure 1-4).31-
36 It has remained unclear if these failures reflect a lack of importance of the lipid whisker model 
in atherogenesis or rather major limitations of the currently available small molecule 
antilipoperoxidants. Supporting the latter hypothesis, vitamin E is non-specific, β-carotene has 
been shown to promote bilayer lipid peroxidation under certain conditions, and astaxanthin lacks 
potency.     
Vitamin E (and the most commonly applied isoform α-tocopherol) is a lipid soluble 
radical trapping antioxidant which has been extensively studied both in vitro and in humans, yet 
it possesses numerous other biological effects which complicate its application as a small 
molecule antilipoperoxidant.37, 38 Vitamin E targets key anti-inflammatory signaling cascades, 
demonstrating direct inhibition of the AP-1 transcription factor and modulation of NF-κB 
6 
signaling through inhibition of protein kinase C activity.39-42 It has also been shown to attenuate 
the activity of lipoxygenase enzymes, perturbing the regulated oxidation of arachidonic acid.43-47 
 
 
The carotenoid natural product β-carotene has similarly undergone extensive study, 
providing complex and conflicting views of its activity. Seminal work from Burton and Ingold 
demonstrated that β-carotene has the capacity to function as an antilipoperoxidant in vitro, yet 
this effect is lost under high concentrations of oxygen.48 In cellular systems, both pro- and 
antioxidant effects of the carotenoid have been observed.49 Our own work has demonstrated that 
β-carotene can function as a prolipoperoxidant in a chemically-defined liposome system.      
The ketocarotenoid astaxanthin has more recently emerged as a promising small 
molecule antilipoperoxidant.50 Astaxanthin has demonstrated potent activity in solution and 
model membrane systems (see Chapter 2). Moreover, in a series of preclinical studies, 
administration of an astaxanthin prodrug resulted in cardioprotective effects in mouse, rat, rabbit, 
and canine models of ischemia/reperfusion injury and a mouse model of atherosclerosis.51-57 
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Figure 1-4. Structures of the small molecules α-tocopherol, β-carotene, and astaxanthin.              
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achieve potent antilipoperoxidant activity represent a major barrier for effective application of 
this small molecule as probe of disease pathogenesis and/or potential therapeutic.58  
We therefore recognized that identification and application of a highly effective small 
molecule inhibitor of non-enzymatic lipid bilayer peroxidation could advance our understanding 
of the role(s) this process plays in the pathogenesis of atherosclerosis and other diseases, and 
possibly function as a starting point for the development of small molecule replacements for 
missing or dysfunctional antilipoperoxidant proteins.59, 60 The following chapters will describe 
our efforts towards the determination and mechanistic characterization of the potent 
antilipoperoxidant activity of the structurally atypical carotenoid peridinin (Chapter 2), and 
application of this small molecule towards elucidating the role of lipid peroxidation in the 
pathogenesis of asthma (Chapter 3).  
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Antilipoperoxidant protein dysfunction is associated with many human diseases including 
atherosclerosis and asthma, suggesting that non-enzymatic bilayer lipid peroxidation may 
contribute broadly to pathogenesis. Small molecule inhibitors of this membrane-localized 
chemistry could in theory promote better understanding and/or treatment of such diseases, but 
the currently available compounds have important limitations and clinical trials have largely 
been disappointing. Enabled by the modular building block-based synthesis of carotenoid natural 
products produced by microorganisms that thrive in environments of extreme oxidative stress, 
we found that the structurally atypical compound peridinin is an exceptionally potent inhibitor of 
non-enzymatic bilayer lipid peroxidation. Solid-state NMR experiments with a synthesized 
isotopologue further linked this potency to heightened effective molarity within lipid bilayers. In 
contrast to the primarily extramembranous localization of the widely utilized but significantly 
less potent antilipoperoxidant astaxanthin, peridinin is completely embedded within and 
physically spans the hydrophobic core of lipid membranes.  Leveraging this chemical probe in 
primary human endothelial cells, we found that the small molecule-mediated mitigation of 
bilayer lipid peroxidation blocks monocyte-endothelial cell adhesion, a key step in atherogenesis. 
These studies suggest that peridinin may possess broad potential as a small molecule 
antilipoperoxidant to better understand the role of lipid membrane peroxidation in human 
disease.  
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Adam G. Hill completed the total synthesis of chlamydaxanthin and developed the 
cellular lipid peroxidation and monocyte binding assays. We collaborated to complete the 
biosynthesis of 13C-astaxanthin and the chemical synthesis of 13C-peridinin. Alex I. Greenwood 
performed all solid-state NMR experiments. Eric M. Woerly developed an early version of the 
chemically-defined liposome system. 
 
Portions of this chapter are adapted from Haley, H. M. S.*; Hill, A. G.*; Greenwood, A. I.; 

















2-1 ANTILIPOPEROXIDANT ACTIVITY OF CAROTENOID NATURAL PRODUCTS  
Carotenoid natural products have garnered significant attention as a promising class of 
small molecule antilipoperoxidants.1-3 They represent a group of terpene-derived compounds of 
which there are approximately 750 known naturally occurring species.4 The terpene scaffold can 
be modified by rearrangement, cyclization, oxidation, and other functionalizations, ultimately 
yielding a final fully hydrocarbon product classified as a carotene, or an oxygen-containing 
compound classified as a xanthophyll.5 The conjugated polyene characteristic of carotenoids 
results in absorption in the 400-500 nm visible range, rendering these molecules highly 
pigmented.6 The electron rich polyene furthermore engenders a low oxidation potential, allowing 
facile reactivity with free radicals and other oxidants such as lipid peroxyl radicals, a chain-
carrying species in the propagation of lipid peroxidation.3, 7, 8  
 Carotenoids possess several mechanisms of antioxidant and/or antilipoperoxidant 
activity.8 Chief among these is the capacity to chemically scavenge oxidizing radical species 
through at least three modes of reactivity, including electron transfer, addition, or allylic 
hydrogen atom abstraction (Figure 2-1).1, 4 Each mechanism results in the formation of a new 
radical species, therefore the observed activity of a carotenoid is a function not only of the rate of 
scavenging, but also the reactivity of the radical carotenoid product.3 Ultimately, the capacity of 
a carotenoid to function as an efficient antilipoperoxidant requires the generation of a species 
with an attenuated capacity to propagate lipid peroxidation, such as the carbon-centered 






Many studies assessing carotenoid-radical reactivity have been performed in organic 
solutions. This raises obvious questions about the extrapolation of such results toward 
increasingly complex lipid membrane, cellular, and whole organism systems, yet they still 
provide insight as to the accessible mechanisms of interaction. Much of the early work focused 
on the radical reactivity of the archetypical dietary carotenoid β-carotene. Burton and Ingold 
demonstrated that β-carotene can function as an antilipoperoxidant, but the effect was not 
linearly correlated to carotenoid concentration.9 This unusual observation was hypothesized to 
result from the propensity for autoxidation of β-carotene itself, particularly under high partial 
pressures of oxygen. Subsequent studies analyzing the products of β-carotene reaction with 
alkylperoxyl radicals provided evidence for carotenoid reactivity via addition and hydrogen atom 
abstraction pathways.2, 10-12 Endoperoxide 2.1, epoxide 2.2, chain cleavage product 2.3, and the 
methanol addition species 2.4 (in presence of trace MeOH) were among several of the molecules 
observed upon exposure of β-carotene to peroxyl radicals derived from the azo initiators 
2,2’azobis(2-methylpropionitrile) (AIBN) or 2,2’azobis(2,4-dimethylvaleronitrile) (AMVN) in 
solution (Figure 2-2).2, 12  
 
 
CAROT + ROO•electron transfer
hydrogen atom abstraction





Figure 2-1. Carotenoids are proposed to react with oxidizing radicals such as the peroxyl radical via at 




 Significant efforts have been made toward more directly observing the transient 
intermediates and products of carotenoid-radical reactivity, with the goal of gaining insight into 
the mechanistic and kinetic features of these processes. Laser flash photolysis, pulse radiolysis, 
and chemical oxidation methods coupled with UV-Vis-NIR absorption spectroscopy and 
electrochemical analysis represent the most commonly applied techniques.3, 7, 13-18 These studies 
have collectively begun to provide a useful understanding carotenoid reactivity, although the 
ambiguity in assigning an observed spectral feature to a specific intermediate renders the 
interpretation of the results inconclusive. Nonetheless, these experiments highlight the influence 
of the structural features of a carotenoid, the identity of the radical species, and perhaps equally 
importantly the properties of the surrounding medium for the observed reactivity.  
 The significance of the surrounding medium is exemplified by the divergent reactivity of 
β-carotene with the (trichloromethyl)peroxyl radical (CCl3O2!) in different environments. In 
solutions of both water:tert-butanol and water:isopropyl alcohol, the formation of  a red-shifted 
species assigned to the β-carotene radical cation was observed by pulse radiolysis.19, 20 
Alternatively, in a heterogeneous micellar environment, a second transiently formed species 


























Figure 2-2. Products illustrating the reactivity of β-carotene and alkyl peroxyl radicals via addition 
and hydrogen atom abstraction pathways.  
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cation.13 The radical cation was specifically suggested to form both via a direct electron transfer 
pathway and decomposition of the adduct.13 
Toward developing an understanding of the structural features that differentiate the 
antilipoperoxidant activity of carotenoids, systematic studies in homogenous lipid solutions or 
heterogeneous micellar and liposomal systems have been reported. The carotenoid series β-
carotene, zeaxanthin, canthaxanthin, and astaxanthin represent a set for which the effects of 
increasing oxidation on the terminal rings can be evaluated (Figure 2-3). Hydroxylation of the 
C3 and 3’ positions of β-carotene provides the zeaxanthin scaffold, while complete oxidation at 
the C4 and 4’ carbons to the carbonyls results in canthaxanthin formation. The corresponding 
oxidations at both C3/3’ and C4/4’ yield astaxanthin.  
 
 
The relative capacities of carotenoids in this series to attenuate lipid peroxidation in 
homogenous solution was consistent across two, albeit quite similar, systems. In a model 
applying AIBN-initiated oxidation of methyl linoleate in chloroform, astaxanthin demonstrated 
the most potent antilipoperoxidant activity, followed in order by canthaxanthin, β-carotene, and 
zeaxanthin.21 The same trend in carotenoid antilipoperoxidant activity was observed for the 
corresponding AMVN-initiated system in hexanes:isopropanol, as quantified by formation of 





































Figure 2-3. Structures of carotenoids displaying an increasing degree of terminal ring oxidation.  
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potent activities of astaxanthin and canthaxanthin were proposed to result from the capacity of 
the conjugated electron-withdrawing carbonyl substituents to stabilize an addition radical, and 
thereby efficiently inhibit the propagation of lipid peroxidation.   
A more complicated and variable picture of antilipoperoxidant activity for the same set of 
carotenoids emerges in heterogeneous systems. In egg yolk phosphatidylcholine (EYPC) 
multilamellar vesicles (MLVs) in which oxidation was initiated by the lipid soluble AMVN, 
astaxanthin emerged as the most potent species followed by zeaxanthin, canthaxanthin, and β-
carotene in order of decreasing activity. Alternatively applying the water-soluble azo-initiator 
2,2’-azobis(2-methylpropionamidine) dihydrochloride  (AAPH) resulted in the increased 
antilipoperoxidant activity of β-carotene relative to canthaxanthin (astaxanthin ~ zeaxanthin > β-
carotene > canthaxanthin).23 Finally, in a micellar system utilizing metmyoglobin iron-induced 
oxidation of methyl linoleate, highly variable trends in carotenoid antilipoperoxidant activity 
with no obvious structural basis were observed.21 For example, the most structurally divergent 
compounds astaxanthin and β-carotene displayed comparably weak activities. Collectively, these 
results reveal that the radical scavenging activity of carotenoid natural products is a complex 
phenomenon dependent upon carotenoid structure, features of the oxidizing radicals, and the 
surrounding medium. Despite the emergence of some reactivity trends and the ability to develop 
mechanistic hypotheses within a single data set, it remains difficult to broadly characterize and 
thereby rationally optimize this activity.  
The capacity of carotenoids to influence the physical properties of lipid membranes 
represents another mechanism through which these small molecules are suggested to exert 
antilipoperoxidant function.24, 25 Hydrophobic van der Waals interactions between the polyene 
backbone and phospholipid tails are proposed to promote carotenoid localization within lipid 
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bilayers. Polar carotenoids possessing oxidation near the termini are specifically thought to span 
the bilayer, allowing placement of the hydrophilic functionality in proximity to the polar lipid 
head groups and the lipid-water interface.4 These molecules have thus been described as 
“molecular rivets” able to generally decrease the fluidity and increase the order parameters of 
lipid membranes in which they are inserted.6 The observed effects of polar carotenoids are 
similar to those of the membrane-embedded sterol cholesterol.24, 25    
NMR, EPR, and fluorescence spectroscopy experiments in model lipid bilayers have 
provided significant evidence for the membrane rigidifying capacity of polar carotenoids, 
including zeaxanthin and astaxanthin.26-29 The physical effect is proposed to result in an 
antilipoperoxidant effect via attenuation of the lateral diffusion or motion of reactive lipid 
hydroperoxides, and therefore an attenuation of the rate of propagation of lipid peroxidation. 
This mechanistic link has been described for carotenoids, yet more extensively characterized in 
the context of cholesterol.29-32 For example, increasing concentrations of cholesterol have been 
demonstrated to attenuate both lipid peroxidation and measurements of lipid motion or lateral 
mobility in liposomes.32, 33 Furthermore, the methyl-β-cyclodextrin mediated depletion of 
cholesterol in erythrocytes resulted in increased membrane fluidity and susceptibility to lipid 
oxidation.34       
These studies collectively demonstrate that carotenoid natural products possess promising 
antilipoperoxidant capacity, yet the number and complexity of the factors which contribute to 
this activity in each molecule has largely precluded the rational and systematic optimization of 
this function. The intricate and sensitive polyene frameworks found in many carotenoids further 
present significant synthetic challenges, limiting rapid access to new compounds. The continued 
application of β-carotene and astaxanthin, both of which possess important limitations (see 
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Chapter 1), exemplifies these difficulties. With the goal of identifying a highly effective small 
molecule inhibitor of non-enzymatic lipid bilayer peroxidation to advance our understanding of 
the specific role(s) this process plays in the pathogenesis of atherosclerosis and other diseases, 
we proposed that context-specific selective pressures may have driven the evolution of 
carotenoid natural products with potent antilipoperoxidant activity in microorganisms that thrive 
in environments of extreme oxidative stress.  
 
2-2 STRUCTURALLY ATYPICAL CAROTENOIDS ISOLATED FROM 
MICROORGANISMS THAT THRIVE IN ENVIRONMENTS OF OXIDATIVE STRESS  
We thus aimed to characterize the antilipoperoxidant activity of the structurally atypical 
carotenoids peridinin, synechoxanthin, and chlamydaxanthin (Figure 2-4). Peridinin (Figure 2-
4a) is an allenic norcarotenoid produced by the photosynthetic dinoflagellate Amphidinium 
carterae.35 In the producing organism, peridinin is localized to the soluble peridinin-chlorophyll-
protein (PCP) complex where it plays critical roles in light harvesting and protection from photo-
mediated oxidation.36-40 Toward its photoprotective capacity, peridinin is proposed to quench the 
high energy triplet excited state of chlorophyll via a Dexter energy exchange mechanism.37 In 
this process, peridinin repeatedly donates a ground state electron and accepts an excited state 
electron from chlorophyll, suggesting a capacity to perform electron transfer without 
concomitant degradation.41, 42 We therefore hypothesized that peridinin may be able to robustly 
quench lipid peroxyl radicals through electron donation to form the corresponding peroxyl anion 
and carotenoid radical cation, followed by reduction of peridinin to regenerate the neutral 
species. Peridinin, through this mechanism, could act as a non-self destructive inhibitor of lipid 
peroxidation.  
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Synechoxanthin (Figure 2-4b) is a structurally unique aromatic dicarboxylate carotenoid 
isolated from the marine cyanobacterium Synechococcus sp. strain PCC 7002.43 The producing 
cyanobacterium is exceptionally resistant to photo-oxidative stress in environments of high light 
intensity.44 Recent work demonstrated that genetic manipulation of the cyanobacterial 
biosynthetic machinery to knock-out production of synechoxanthin attenuated ROS resistance 
and growth of the organism, suggesting that this carotenoid may play critical antioxidant and/or 



















































































































Figure 2-4. Building block-based syntheses of carotenoid natural products isolated from organisms 
that thrive in environments of extreme oxidative stress.    
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The bis-glycolipidated carotenoid di[(6-O-oleoyl-β-D-glucopyranosyl)oxy]-astaxanthin 
(chlamydaxanthin) (Figure 2-4c) is produced by the snow alga Chlamydomonas nivalis.46 It is 
responsible for the “watermelon snow” phenomenon in which patches of snow turn dark red due 
to increased carotenoid production during times of peak light intensity. We hypothesized that the 
conspicuous glycolipid tails on this carotenoid may anchor the polyene of chlamydaxanthin 
within the hydrophobic core of lipid bilayers, and thus maximize its concentration at the site 
critical for antilipoperoxidant activity.  
For each of the carotenoid natural products, isolation from the producing organism is 
inefficient and has therefore represented a major barrier towards studying their 
antilipoperoxidant potential.47 Chemical synthesis represents an alternative means of accessing 
such molecules and their derivatives, but the large size and high degree of complexity of these 
compounds presents a host of challenges. With the goal of eliminating such synthesis 
bottlenecks, our group has developed a strategy, analogous to peptide coupling, in which the 
single Suzuki-Miyaura cross-coupling reaction is employed iteratively to assemble a collection 
of bifunctional haloboronic acid building blocks protected as the corresponding N-
methyliminodiacetic acid (MIDA) boronates (Figure 2-5).48-52 A key feature of this platform, 
termed iterative cross-coupling (ICC), is that all of the required functional groups, oxidation 
states, and stereochemistry are pre-installed into the building blocks, and then faithfully 
translated into the growing product due to the mild and stereospecific nature of the cross-
coupling-based assembly. Dr. Eric Woerly and Dr. Seiko Fujii employed this approach to 





2-3 BUILDING BLOCK-BASED SYNTHESES OF CAROTENOID NATURAL 
PRODUCTS  
 Peridinin and synechoxanthin were prepared utilizing iterative assembly of the necessary 
MIDA boronate building blocks as detailed in the published routes (Figure 2-4).53, 54  Adam Hill 
developed a modular semi-synthetic route to chlamydaxanthin in which astaxanthin was bis-
functionalized via stereocontrolled glycosidation with a glycolipidated sugar donor containing 
the 4-(tert-butyl-dimethyl-silyl)oxy-2,2-dimethyl-butyric acid (TDMB)55 protecting group 
(Figure 2-6). This protecting group both facilitated the highly stereoselective formation of the 
required β-glycosidic linkages via neighboring group participation and allowed for global 






















































Iterative peptide coupling Iterative cross-coupling
Figure 2-5. The Suzuki-Miyaura cross-coupling reaction can be utilized iteratively to assemble 
collections of haloboronic acid building blocks. This strategy is analogous to iterative peptide 




2-4 ANALYSIS OF ANTILIPOPEROXIDANT ACTIVITY  
 The disappointing results of clinical trials applying β-carotene, α-tocopherol and 
astaxanthin suggest either the lack of a key causative connection between bilayer lipid 
peroxidation and atherosclerosis, or a failure of these small molecules to potently and selectively 
inhibit lipid membrane oxidation. Importantly, significant evidence for the latter hypothesis 
exists. Experiments have shown that β-carotene can act as a prolipoperoxidant under certain 
conditions, α-tocopherol has off-target biological effects, and astaxanthin lacks potency (see 
Chapter 1 for discussion of these topics).  
 We sought to confirm the limitations of these compounds and characterize the 
antilipoperoxidant activity of the structurally atypical carotenoids peridinin, synechoxanthin, and 
chlamydaxanthin. To exclusively probe non-enzymatic bilayer lipid peroxidation and maximize 
reproducibility, we developed a biologically-relevant fully synthetic and therefore chemically 
defined liposome system. This minimizes the inherent variability observed with the use of 
natural lipid mixtures such as EYPC, which are often applied in similar assays. Specifically, we 
prepared large unilamellar vesicles (LUVs) comprised of 75 mol% 1-palmitoyl-2-oleoyl-sn-




































R = TDMB1. HF•pyridine
2. DBU, THF
    27% R = H (chlamydaxanthin)
astaxanthin
Figure 2-6. Synthesis of the glycolipidated carotenoid chlamydaxanthin.      
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stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine. The PUFAs contain a small concentration 
of lipid hydroperoxides (LOOH) derived from autoxidation. Exposure of these pre-existing 
LOOH to CuCl2 initiates lipid peroxidation, presumably via conversion of LOOH to the 
corresponding lipid peroxyl radical (LOO!).56, 57 The extent of lipid peroxidation was quantified 
by measuring formation of the lipid decomposition product malondialdehyde (MDA) via HPLC 
analysis of the corresponding thiobarbituric acid adduct (Figure 2-7).58, 59  
 
 
 Analysis of β-carotene in the liposome system demonstrated the prolipoperoxidant 
activity of this carotenoid as evidenced by increased MDA formation relative to vehicle, 
therefore we decided to pursue no further study of this compound (Experimental Section, Figure 
2.21). Both α-tocopherol and astaxanthin demonstrated weak antilipoperoxidant activity (Figure 
2-8a). Specifically, concentrations of >5 mol% relative to lipid were required to approach 90% 
protection against the non-enzymatic chemical oxidation of membrane PUFAs. We therefore 
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Figure 2-7. The fully synthetic chemically-defined liposome assay utilizes 75 mol% POPC and 25 
mol% PUFA.  Lipid peroxidation is analyzed by HPLC detection of the thiobarbituric acid adduct of 
the lipid decomposition product malondialdehyde.         
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membrane system. Chlamydaxanthin showed no improvement relative to astaxanthin, yet 
synechoxanthin was significantly more effective, and peridinin demonstrated exceptionally 
potent antilipoperoxidant activity (Figure 2-8a). A concentration of 0.5 mol% peridinin achieved 
nearly complete protection against non-enzymatic bilayer lipid peroxidation, more than an order 
of magnitude lower than the concentration of α-tocopherol and astaxanthin required to achieve 
similar activity. Analysis of the rate of lipid peroxidation, as determined via both MDA formation 
and PUFA consumption (Figures 2-8b,c), further confirmed that while 0.5 mol% astaxanthin 
minimally attenuated this process over the course of 10 hours, the same concentration of 













































































































Figure 2-8. Peridinin is a potent antilipoperoxidant in liposomes and human cells. (a) Small molecule-
mediated lipid protection in chemically defined liposomes as determined by inhibition of MDA 
formation. (b) Time-dependent inhibition of MDA formation and (c) PUFA (20:4) consumption in 
liposomes. (d) Lipid protection in primary HUVECs as determined by MDA formation. Error bars = 
SD for a-c and SEM for d, ** p < 0.01, ***p < 0.001, NS = not significant, * = comparison to vehicle 
and # = comparison to astaxanthin.            
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  To probe the corresponding antilipoperoxidant capacity of the small molecules in a more 
complex and atherosclerosis-relevant human cellular system, we developed an assay utilizing 
primary human umbilical vein endothelial cells (HUVECs). The cellular stress caused by 
incubating the HUVECs in serum-free basal media led to the reproducible onset of spontaneous 
endogenous lipid peroxidation. We monitored lipid peroxidation via MDA quantification, and 
cell counts were measured at the beginning and end of the assay to confirm differences in MDA 
were not the result of differences in cell number (Experimental Section, Figure 2-23).  
 Consistent with results in the model membrane assay, we found peridinin to be very 
potent in HUVECs, necessitating a concentration of 140 nM to reach 50% inhibition of lipid 
peroxidation (Figure 2-8d). Astaxanthin showed only weak activity, requiring >40 µM to reach 
the same level of inhibition. Notably, α-tocopherol demonstrated significantly improved 
antilipoperoxidant activity in the cellular system in contrast to the limited potency observed in 
liposomes. This divergence suggests that the antilipoperoxidant activity of α-tocopherol in vivo is 
due to mechanisms other than direct inhibition of non-enzymatic lipid bilayer peroxidation. 
Peridinin is also an order of magnitude more potent than the recently reported antilipoperoxidant 
OH-pen (Experimental Section, Figure 2.24).  
 
2-5 MECHANISTIC CHARACTERIZATION OF THE POTENT 
ANTILIPOPEROXIDANT ACTIVITY OF PERIDININ  
 We next aimed to characterize the mechanistic underpinnings of the exceptional potency 
of peridinin, particularly in contrast with the structurally-related but less potent astaxanthin. We 
recognized that this would provide fundamental insight towards understanding the 
antilipoperoxidant activity of carotenoid natural products and furthermore strengthen the utility 
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of peridinin as a small molecule antilipoperoxidant probe compound. Three specific hypotheses 
were considered (Figure 2-9): (i) Peridinin more effectively attenuates lipid lateral diffusion and 
thereby attenuates the propagation of lipid peroxidation. (ii) Peridinin is able to more rapidly 
quench lipid peroxyl radicals. (iii) Peridinin is more localized within the lipid bilayer, and 
therefore has a higher effective molarity at the site of lipid peroxidation.  
 
 
2-6 PERIDININ DOES NOT MORE EFFECTIVELY ATTENUATE LIPID MOTION  
 The first hypothesis predicts that peridinin exerts antilipoperoxidant activity by more 
effectively attenuating the rate of lipid lateral diffusion than astaxanthin, thereby slowing the rate 
of free-radical propagation of lipid peroxidation (Figure 2-9i). This correlation has been 
suggested for other carotenoids and more extensively characterized in the context of the 
membrane-embedded sterol cholesterol (see section 2-1). Solid-state NMR (SSNMR) and 
solution NMR were applied to quantify the effects of carotenoid incorporation on lipid lateral 
































Figure 2-9. Mechanistic hypotheses to explain the potent antilipoperoxidant activity of peridinin 
relative to the less potent astaxanthin. Hypothesis (i) suggests that peridinin is able to more effectively 
attenuate lipid lateral diffusion. Hypothesis (ii) suggests that peridinin chemically reacts at a faster 
rate. Hypothesis (iii) suggests that peridinin has a higher propensity for membrane insertion.            
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 Liposomes containing a range of carotenoid concentrations for which antilipoperoxidant 
activity is observed (0.5-5% carotenoid relative to lipid) or cholesterol as a positive control were 
prepared. Carotenoid or cholesterol containing MLVs were utilized for SSNMR analysis, and 
LUVs prepared by the same method as for lipid peroxidation analysis were utilized for solution 
NMR. Increasing concentrations of peridinin, astaxanthin, and cholesterol each resulted in 
similar, concentration-dependent increases in lipid R2, indicative of a decrease in the rate of lipid 
lateral diffusion (Figure 2-10a,b). The comparable effects of peridinin and astaxanthin towards 
modulating lipid methylene relaxation rate provided strong initial evidence that this mechanism 




















































































































Figure 2-10. Interrogating mechanistic models one and two. (a) Lipid lateral diffusion as determined 
by SSNMR and (b) solution NMR. (c) Antilipoperoxidant effects of cholesterol, peridinin, and 
astaxanthin in liposomes. (d) Single electron donation from the carotenoids to ABTS!+. (e) 
Stoichiometric reactivity of the carotenoids with tBuOOH/CuCl2. Error bars = SD, ***p < 0.001, NS = 
not significant.    
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 We recognized, however, that we could further probe this mechanism via concomitant 
analysis of the antilipoperoxidant activities of all three small molecules. In contrast to the 
observed similar effects on lipid diffusion, the antilipoperoxidant activity of these three 
molecules diverged. Astaxanthin and peridinin demonstrated substantial inhibition of lipid 
peroxidation at 3 mol%, while 3 mol% cholesterol showed no inhibition of lipid peroxidation 
(Figure 2-10c). A much higher concentration of cholesterol (24 mol%), which caused a 
significantly greater reduction in lipid lateral diffusion, was required to achieve a similar level of 
antilipoperoxidant activity. This divergence in concentration dependence for inhibition of lipid 
lateral diffusion and inhibition of lipid peroxidation indicates that the attenuation of diffusion is 
not a key factor in potent antilipoperoxidant activity of peridinin. 
 
2-7 PERIDININ DOES NOT MORE RAPIDLY QUENCH PEROXYL RADICALS 
The second mechanistic hypothesis suggests that peridinin is a more potent 
antilipoperoxidant than astaxanthin because it more rapidly quenches or scavenges lipid peroxyl 
radicals, a chain carrying species in the propagation of lipid peroxidation (Figure 2-9ii, see also 
section 2-1). To test this, we investigated two important modes of radical quenching reactivity: 
(i) single electron transfer from the carotenoid to a radical species and (ii) stoichiometric 
reactivity of the carotenoid with an oxygen-centered radical. Solution phase assays in which all 
species are fully soluble were utilized to specifically isolate carotenoid chemical reactivity from 
the complicating factors of membrane dynamics and localization.  
To probe the capacity of astaxanthin and peridinin to perform single electron transfer, we 
utilized a decolorization assay based on electron donation to the pre-formed radical cation 
derived from oxidation of 2,2’-azino-bis(3-ethylbenzothioazoline-6-sulfonic acid) (ABTS).61, 62 
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Both astaxanthin and peridinin were able to rapidly perform single electron donation, as 
indicated by loss of the ABTS!+ signal upon carotenoid addition (Figure 2-10d).  We observed, 
however, a faster rate of electron transfer from astaxanthin. The half-life of ABTS!+ was 2.3 ± 
0.1 minutes upon exposure to astaxanthin, and 8.3 ± 0.1 minutes upon treatment with peridinin.   
We then assessed the stoichiometric reactivity of astaxanthin and peridinin towards 
oxygen-centered radical species. To mirror the conditions of the liposome-based lipid 
peroxidation assay, we assessed the stability of each carotenoid in solution with tert-butyl 
hydroperoxide and the initiator CuCl2. Interestingly, whereas astaxanthin was fully consumed 
over the course of 2 hours, peridinin underwent limited degradation under the same conditions 
(Figure 2-10e). These data are consistent with a much faster rate of self-destructive peroxyl 
radical quenching for astaxanthin.  
Collectively, these experiments suggest that astaxanthin exerts antilipoperoxidant activity 
via both stoichiometric self-consumptive and potentially self-preserving electron transfer 
mechanisms, while peridinin may exert its activity primarily via a non-self-destructive and 
potentially catalytic single-electron transfer mechanism. Consistent with this, we found that 
peridinin is only minimally consumed as it protects against lipid peroxidation in liposomes 
(Figure 2-11a,b). Astaxanthin undergoes a significantly greater extent of degradation. Peridinin 
furthermore protects astaxanthin from consumption upon co-incorporation in both the liposome 







2-8 PERIDININ HAS A HIGHER EFFECTIVE MOLARITY IN LIPID MEMBRANES  
The third mechanistic hypothesis predicts that peridinin has an increased propensity 
relative to astaxanthin to insert into the hydrophobic core of lipid bilayers, thereby increasing its 
effective molarity at the site necessary to promote antilipoperoxidant activity (Figure 2-9iii). 
Interrogating this model requires assessment of the location of both carotenoids relative to the 
lipid bilayer with angstrom-level resolution, which is challenging due to the limited number of 
suitable experimental methods. We thus sought to apply a SSNMR paramagnetic relaxation 
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Figure 2-11. Peridinin undergoes minimal consumption and protects astaxanthin from consumption 
upon co-incorporation. (a,b) Peridinin is minimally consumed and astaxanthin is significantly 
consumed during lipid oxidation in liposomes. Peridinin protects astaxanthin from consumption upon 
co-incorporation. (c,d) Peridinin protects astaxanthin from consumption in the solution phase 
tBuOOH/CuCl2 assay. For c, sample contains 33 µM of each carotenoid, 33 µM CuCl2, and 16.5 mM 
tBuOOH. For d, sample contains 16.5 µM of each carotenoid, 33 µM CuCl2, and 16.5 mM tBuOOH. 
Error bars = SD.     
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laboratories able to probe small molecule-membrane interactions with the necessary precision 
(Figure 2-12).  
 
 
In this experiment, the PRE of a 13C nuclei proximal to a lipid-appended stable radical 
spin label, such as 4,4-dimethyloxazolidine-N-oxyl (DOXYL), can be quantified by measuring 
the longitudinal relaxation rate (R1 = 1/T1) of the 13C nuclei. This PRE effect is detected for 
distances up to ~20 Å and allows for direct measurement of the intramembranous carotenoid 
population (Figure 2-12). Proceeding with this experiment required access to highly 13C-enriched 
astaxanthin and peridinin. Uniformly 13C-enriched astaxanthin (13C-astaxanthin) was produced 
via biosynthesis utilizing the red yeast X. dendrorhous strain UBV-AX2 with fully 13C-labeled 
glucose as the primary carbon source.63 This growth protocol yielded 65% 13C incorporation and 
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Figure 2-12. Solid-state NMR paramagnetic relaxation enhancement experiment can determine the 
localization of a 13C carotenoid with respect to a lipid bilayer (a) Lipids utilized in SSNMR PRE 
experiment. (b) No PRE is expected for an extramembranously localized carotenoid, while a robust 




Due to the challenges associated with the production and isolation of peridinin from its 
producing organism, this compound is not amenable to a biosynthetic strategy for isotopologue 
generation. However, given the inherent efficiency and flexibility of the known MIDA boronate 
building block-based total synthesis, we were in the unique position to rapidly access site-
specifically 13C-labeled derivatives by incorporating the corresponding site-selectively labeled 
building blocks (BBs) into the same synthetic route. As representative positions spanning the 
polyene core and possessing resolved carbon signals in the 13C NMR spectrum, we selected the 
C7 and C7’ polyene carbons near the terminal rings contained in BB1 and BB4, and the C15 and 
C15’ carbons at the center of the polyene contained in BB3 for 13C enrichment (Figure 2-13b).  
Installation of the 13C-labeled C7’ and C7 carbons commenced with lithiation and 
trapping of vinyl iodide 2.5 with 13C paraformaldehyde, followed by Sharpless epoxidation, 
Swern oxidation, and Colvin rearrangement to furnish alkyne 2.9 (Figure 2-14). This 










































































Figure 2-13. 13C-labeled carotenoids (a) 13C-astaxanthin was accessed via biosynthesis. (b) 13C-
peridinin was accessed via building block synthesis.    
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corresponding MIDA boronate, or to BB4 through TBS deprotection, iodoallene formation, and 
acetate and TMS protection.  
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Figure 2-14.  Synthesis of 13C-peridinin utilizing the building block-based ICC platform. 
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Toward the synthesis of 13C-labeled BB3, bis-13C labeled trimethylsilylacetylene 2.14 
gave rise to the isotopes at C15 and C15’. Alkyne germylation, silyl deprotection, and 
hydrostannylation yielded the 13C2 bismetalated olefin 2.16. Selective Stille coupling at the vinyl 
stannane to dienyl iodide 2.17 followed by iododegermylation afforded 13C-labeled BB3.  
Iterative rounds of boron deprotection and stereospecific Suzuki-Miyaura cross-coupling 
allowed for the assembly of the three 13C-labeled and single natural abundance building blocks. 
Base-mediated hydrolysis of BB1 to the boronic acid and coupling to BB2 provided the 
intermediate tetraene 2.19 in 57% yield. Transesterification to the corresponding reactive pinacol 
boronic ester allowed coupling to BB3 to form heptaene 2.20 with a modest 39% yield. 
Subsequent in situ hydrolysis of the heptaenyl MIDA boronate and coupling to BB4 provided the 
protected peridinin scaffold in 63% yield. Final global desilylation yielded C7, C7’, C15, C15’ 
13C4-labeled peridinin (13C-peridinin) (Figure 2-14). 
We prepared samples of 13C-astaxanthin in POPC bilayers (MLVs, 25:1 molar ratio 
lipid:astaxanthin) and used a series of 13C chemical shift correlation experiments (including 2D 
13C-13C with POST-C7 mixing and 3D 13C-13C-13C with SPC7 and DARR mixing in the first and 
second indirect dimensions) to de novo assign the 13C resonances of astaxanthin. The 13C-
astaxanthin samples unexpectedly showed a mixture of two populations (Figure 2-15a). A 
corresponding group of samples were prepared with 13C-peridinin and we assigned the 13C 
resonances from the corresponding solution phase 13C shifts. The 13C-peridinin samples 







PRE measurements were performed for a POPC only control, the 13C-astaxanthin-POPC 
sample, and the 13C-peridinin-POPC sample in the presence of 5 mol% 16-DOXYL-PC. 
Measurement of the PRE effect on the POPC carbons shows a maximum value on carbons 16 
and 17 and a steady decrease in PRE value for carbons approaching the phosphatidylcholine 
head group, consistent with a well-formed membrane in which the 16-DOXYL spin label 
assumes a position near the center of the bilayer (Figure 2-15c).  
Analysis of the T1 relaxation curves for astaxanthin carbons 1-4 in the 13C-astaxanthin 
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Figure 2-15. SSNMR analysis of carotenoid localization. (a) 13C-13C correlation spectrum for the 13C-
astaxanthin MLV sample revealed multiple astaxanthin populations. (b) A single 13C-peridinin 
population was observed. (c) PRE effect for POPC, (d) 13C-astaxanthin, and (e) 13C-peridinin 
containing bilayers with the 16-DOXYL PC spin label. 
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sample yielded a two component fit, with the major component comprising 78 ± 2% and a minor 
component comprising 22 ± 2% of the total signal. The major astaxanthin population exhibited 
no observable PRE effect, while the minor astaxanthin population demonstrated a significant 
PRE effect (Figure 2-15d). These results are consistent with the conclusion that the majority of 
astaxanthin resides outside the hydrophobic core of the lipid bilayer. When we alternatively 
analyzed the 13C-peridinin sample, a large PRE effect was observed for all four labeled carbons 
(Figure 2-15e). Thus, the single peridinin population is fully embedded within the lipid bilayer.  
We also noted in the 13C-peridinin sample containing the 16-DOXYL spin label that the 
15 and 15’ carbons showed a significantly larger PRE effect (8-10 s-1) than the 7 and 7’ carbons 
(3-4 s-1). This suggested that peridinin is likely oriented parallel to the bilayer normal, thus 
spanning the hydrophobic lipid core. SSNMR spin-diffusion experiments provided a second line 
of evidence in support of this parallel orientation. Strong water-peridinin and lipid-peridinin 
correlations were observed for the 7 and 7’ carbons, but only lipid-peridinin correlations were 
observed for the 15 and 15’ positions (Figure 2-16a). 
To further probe this putative orientation of peridinin in the bilayer, we performed a 
series of PRE experiments each employing a different DOXYL-PC species with the spin label 
positioned at increasing depth in the membrane. Specifically 5, 7, 10, 12, 14, or 16-DOXYL-PC 
lipids were applied (Figure 2-16b).  The relative magnitude of PRE observed for carbons 7/7’ 
and 15/15’ across this series further support a parallel orientation of peridinin with respect to the 
bilayer normal (Figure 2-16c). For the 5-DOXYL-PC and 7-DOXYL-PC probes, a significantly 
larger PRE was observed for C7/7’ relative to C15/15’. The opposite was observed for the 14-
DOXYL-PC and 16-DOXYL-PC lipids, and a transition between these two extremes was 




Thus, in contrast to the primarily extramembranous localization of astaxanthin, peridinin 
is fully embedded in the lipid bilayers and spans the hydrophobic core. We conclude that the 
corresponding high effective molarity at the site of the targeted hydrocarbon oxidation chemistry 
is critical for the capacity of peridinin to function as a potent inhibitor of non-enzymatic bilayer 
lipid peroxidation.  
 
2-9 BILAYER LIPID PEROXIDATION IN ENDOTHELIAL CELLS PLAYS A KEY 
ROLE IN THE PROMOTION OF MONOCYTE BINDING  
With this potent and well-characterized inhibitor of bilayer lipid peroxidation in hand, we 
employed peridinin to probe the relevance of the lipid whisker model in monocyte-endothelial 
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Figure 2-16.  SSNMR experiments provide evidence for a membrane-spanning orientation of 
peridinin. (a) Spin diffusion from water and POPC lipid to the peridinin 7 and 15 carbons. (b) Series 
of DOXYL spin labels. (c) PRE effect for the peridinin 7 and 15 carbons in the presence of different 
DOXYL spin labels.   
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oxidized phospholipids (OxPUFA) caused a significant increase in monocyte binding (Figure 2-
17a).64, 65 Alternatively stressing the endothelial cells by switching to basal media caused a 
concomitant increase in both endogenous lipid peroxidation and monocyte binding (Figure 2-
17a,b).  Incubation with 2 µM astaxanthin as a weakly potent negative control resulted in no 
significant attenuation of either lipid peroxidation or monocyte binding. In stark contrast, the 
addition of 2 µM peridinin caused a significant reduction in both lipid peroxidation and the 
number of bound monocytes. Microscopic analysis of these samples was consistent with the 
conclusion that the bilayer localization of the carotenoids in HUVECs mirrors that in liposomes 
as indicated by SSNMR. Specifically, dark aggregates were observed in the astaxanthin but not 
the peridinin or DMSO treated cells (Figure 2-17c). Collectively, these results indicate that the 
small molecule-mediated attenuation of bilayer lipid peroxidation is able to mitigate monocyte-
endothelial cell adhesion. This provides evidence for the role of the lipid whisker model in 
atherogenesis and suggests the capacity of a bilayer-localized potent antilipoperoxidant to 
meaningfully address this pathway. These studies further indicate that peridinin and astaxanthin 
may have broad potential as a pair of chemical probes to better understand the role of bilayer 
lipid peroxidation in the pathogenesis of human disease. 
 
2-10 TOTAL SYNTHESIS OF THE AROMATIC APOLAR CAROTENOID 
RENIERAPURPURIN 
 Analysis of the antilipoperoxidant capacity of the structurally atypical carotenoid natural 
products in the model membrane assay revealed the promising activity not only of peridinin, but 
also the aromatic dicarboxylate synechoxanthin produced by the cyanobacterium Synechococcus 
sp. strain PCC 7002. Compellingly, mutants of this cyanobacterium containing the inactivated 
41 
CruE enzyme necessary for the production of the intermediate renierapurpurin and 
synechoxanthin from β-carotene exhibited significantly increased levels of ROS and sensitivity 




concentration of intracellular ROS and increased doubling time relative to the wild-type 
cyanobacterium under high light conditions.44, 45 β-Carotene, renierapurpurin, and 
synechoxanthin thus represent an interesting series of biosynthetically related carotenoids in 
which to study the effects of tailoring enzyme modifications that collectively transform the 


















































DMSO OxPUFA DMSO 2 µM astaxanthin 
100 µm 
2 µM peridinin 
growth media basal media 
Figure 2-17.  (a) Peridinin but not astaxanthin inhibits the binding of monocytes and (b) lipid 
peroxidation in HUVECs. (c) Images of HUVECs show monocyte binding. Dark aggregates are 
observed only in the astaxanthin-treated samples. Error bars = SEM, *p , 0.05, **p < 0.01, NS = not 
significant, * = comparison to vehicles, # = comparison to astaxanthin.     
42 
synthesis of renierapurpurin to complement the published route for synechoxanthin would 
provide access to both atypical carotenoids and thereby enable direct comparison of the anti- or 
prolipoperoxidant capacities of the three carotenoids.  
 
 
 We recognized that the completed total synthesis of synechoxanthin provided a flexible 
roadmap for the synthesis of renierapurpurin. Applying an ICC strategy, renierapurpurin was 
initially retrosynthesized into three building blocks, BB5-BB7, each of which were prepared 
using known procedures (Figure 2-19a).54, 66 The synthesis began with the coupling of the 
capping aryl iodide BB5 to the reactive pinacol boronic ester terminus of bisborylated diene BB6, 
which afforded diene 2.21 in 70% yield (Figure 2-19b). Halodeborylation of 2.21 was proposed 
to unmask a new electrophilic halide 2.22 for a second iteration of coupling to BB6, however, 
exposure of 2.21 to I2 and base (NaOH or NaOMe) consistently resulted in an inseparable 





























Figure 2-18.  Biosynthesis of synechoxanthin from β-carotene via the intermediate renierapurpurin in 




We therefore redesigned the route, recognizing that the same dienyl MIDA boronate 2.21 
could alternatively be deprotected to the corresponding pinacol boronic ester via 
transesterification, which would subsequently be coupled to a new building block, iodide BB8 
(Figure 2-20). These transformations proceeded as planned, yielding tetraenyl MIDA boronate 
2.24 as a single stereoisomer in 39% yield. The C2 symmetry of renierapurpurin allowed for a 
final highly convergent bidirectional cross-coupling. Specifically, the in situ release of two 
equivalents of boronic acid derived from tetraenyl MIDA boronate 2.24 and double cross-
coupling to trans-1-iodo-2-bromoethylene BB7 yielded renierapurpurin in an unoptimized 20% 
yield. We chose to employ a direct release strategy for the last step because it had previously 
been shown in our lab to be the most productive method for late-stage couplings to generate 




































































Figure 2-19.  (a) Initial retrosynthesis of renierapurpurin to three building blocks and (b) forward 
synthesis. Iododeborylation of the aryl diene 2.21 results in an inseparable mixture of products.       
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desired target, the conditions for the final coupling remain unoptimized and it is anticipated that 
substantially higher yields can be obtained. The antilipoperoxidant capacities of β-carotene, 
renierapurpurin, and synechoxanthin have yet to be concurrently tested in a single assay, 
therefore this remains an interesting future direction for the project.   
 
 
2-11 SUMMARY AND CONCLUSIONS   
Guided by the hypothesis that selective pressures may have driven the evolution of potent 
small molecule antilipoperoxidants in organisms that thrive in environments of extreme 
oxidative stress, we found that the structurally atypical carotenoid peridinin is a potent inhibitor 
of non-enzymatic bilayer oxidation. The capacity of this carotenoid to fully insert within lipid 
membranes is critical for its activity. Peridinin was applied as an antilipoperoxidant probe 























































































Figure 2-20.  (a) Revised retrosynthesis of renierapurpurin and (b) forward synthesis.      
45 
of atherosclerosis. We found that the small molecule-mediated inhibition of bilayer oxidation in 
human endothelial cells can concomitantly attenuate monocyte-endothelial binding, indicating 
the relevance of the lipid whisker model in the onset of atherogenesis. These results further 
suggest that peridinin may be able to help clarify the role of lipid peroxidation in a multitude of 
human diseases for which this process has been proposed to be a key driver of pathogenesis.  
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 CHAPTER 2 
EXPERIMENTAL SECTION 
General Methods.  
Materials. Commercially available materials were purchased from Sigma-Aldrich, Alfa-Aesar, 
Avanti Polar Lipids, Cambridge Isotope Laboratories, Fisher Scientific, Lonza, ATCC, Corning, 
or Gibco and were used without further purification unless stated otherwise. Natural abundance 
astaxanthin was a gift from BASF. Peridinin was synthesized as reported by Woerly and 
coworkers.1 Synechoxanthin was synthesized as reported by Fujii and coworkers.2 Unless stated 
otherwise, all of the solvents were dispensed from a solvent purification system that passes 
solvents through packed columns according to the method described by Pangborn and coworkers 
(THF, Et2O, CH3CN, CH2Cl2: dry neutral alumina; hexanes, toluene: dry neutral alumina and Q5 
reactant; DMSO, DMF, CH3OH: activated molecular sieves).3 Triethylamine, diisopropylamine, 
pyridine, and 2,6-lutidine were freshly distilled under an atmosphere of nitrogen over CaH2. 
Water was dispensed from a MilliQ water purification system (Millipore Corporation) unless 
stated otherwise.  
 
General experimental procedures and spectral analysis. Unless noted, all reactions were 
performed in flame dried round bottom flasks, Schlenk flasks fitted with rubber septa, or glass 
vials under a positive pressure of argon or nitrogen. Organic solutions were concentrated via 
rotary evaporation under reduced pressure with a bath temperature of 35-40 °C. Reactions were 
monitored by analytical thin layer chromatography (TLC) performed using the indicated solvent 
on E. Merck silica gel 60 F254 plates (0.25mm). Compounds were visualized by exposure to a 
UV lamp (λ = 254 nm) and/or a solution of stain (KMnO4, CAM = ceric ammonium molybdate 
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or PMA = phosphomolybdic acid) followed by brief heating using a Varitemp heat gun. Column 
chromatography was performed using standard methods4 or on a TeledyneIsco CombiFlash Rf 
purification system using Merck silica gel grade 9385 60Å (230-400 mesh). Unless otherwise 
noted, compounds were adsorbed onto non acid-washed Celite in vacuo which was then loaded 
on top of a silica gel column or into a CombiFlash cartridge. 1H NMR spectra were recorded at 
23 °C on one of the following instruments: Varian Unity 400, Varian Unity 500, Varian Unity 
Inova 500NB, Varian VXR 500. Chemical shifts (δ) are reported in parts per million (ppm) 
downfield from tetramethylsilane and referenced to residual protium in the NMR solvent 
(CHCl3, δ = 7.26; acetone-d6, δ = 2.05, center line). Data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b = broad, app = 
apparent), coupling constant (J) in Hertz (Hz), and integration. 13C NMR spectra were recorded 
at 23 °C on a Varian Unity 500. Chemical shifts (δ) are reported in ppm downfield from 
tetramethylsilane and referenced to carbon resonances in the NMR solvent (CDCl3, δ = 77.0, 
center line; acetone-d6, δ = 29.80, center line) or to added tetramethylsilane (δ = 0.00). Carbons 
bearing boron substituents were typically not observed (quadrupolar relaxation). High resolution 
mass spectra (HRMS) were performed by Furong Sun and Haijun Yao at the University of 
Illinois School of Chemical Sciences Mass Spectrometry Laboratory. UV-Vis analyses were 
performed on a Shimadzu PharmaSpec UV-1700 spectrophotometer or a BioTek Synergy H1 
Hybrid Reader. 
 
HPLC Purification and analysis. Preparative-scale HPLC purification was performed using an 
Agilent 1260 series instrument equipped with a multiple wavelength detector and a Waters 
SunFire Prep C18 OBD 5 µm 30 × 150 mm column at a flow rate of 25 ml/min. Semi-
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preparative scale HPLC purification was performed using an Agilent 1200 series instrument and 
a Waters SunFire Prep C18, 5 µm, 10 x 250 mm. All analytical HPLC analysis was performed 
using an Agilent 1200 series instrument equipped with a variable wavelength detector and 
analytical Agilent Eclipse XDB-C18, 5 µm, 4.6 x 150 mm column. All HPLC solvents were 
filtered through 0.2-µm Millipore filters before use.  
 
HPLC methods. The methods below were used for small molecule analysis by analytical HPLC.   
Astaxanthin  
Isocratic 90:10 MeOH:H2O, detect at 478 nm, 2 mL/min, tR ~ 5.7 min 
Peridinin 
Isocratic 90:10 MeOH:H2O, detect at 468 nm, 2 mL/min, tR ~ 1.9 min 
Chlamydaxanthin 
 Isocratic 85:15 MeOH:acetone, detect at 478 nm, 2 mL/min, tR ~ 6.1 min  
Synechoxanthin 
70:30 MeOH:25 mM NH4OAc to100 MeOH over 10 min, detect at 478 nm,  1.75 
mL/min, tR ~ 6.2 min 
α-Tocopherol 
 Isocratic 90:10 MeCN:MeOH, detect at 208 nm, 2 mL/min, tR ~ 10.8 min 
Cholesterol 
 Isocratic 90:10 MeCN:MeOH, detect at 212 nm, 2 mL/min, tR ~ 13 min 
β-Carotene 
 Isocratic 40:35:25 MeCN:MeOH:THF, detect at 464 nm, 2 mL/min 
MDA-TBA adduct 
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Isocratic 67:20:13 MeCN:MeOH:50mM KH2PO4, detect at 533 nm, 1.5 mL/min, tR ~ 2.1 
min  
 
I. ASSAY PROCEDURES 
General Procedures for Liposome Preparation. 
Materials. All lipids were purchased from Avanti Polar Lipids as 25 mg/mL or 10 mg/mL 
solutions in CHCl3, were stored at -20 °C under an atmosphere of dry argon, and were used 
within 1 month of opening. The lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (16:0-
18:1 PC, POPC), 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (18:0-20:4 PC, PUFA) 
and 1-palmitoyl-2-stearoyl-(X-DOXYL)-sn-glycero-3-phosphocholine (X-DOXYL-PC, where X 
= 5, 7, 10, 12, 14, 16) were used.  
 
Preparation of small molecule solutions. Solutions of the small molecules were prepared in the 
indicated solvents directly prior to use. Peridinin was dissolved in THF at a concentration of 3.8 
or 5.5 mg/mL. Astaxanthin was dissolved in THF at a concentration of 3.8 or 7.7 mg/mL. 
Synechoxanthin was prepared in 5% NEt3 in DMSO at a concentration of 5.1 mg/mL. 
Chlamydaxanthin was prepared in THF at a concentration of 2.9 mg/mL. β-Carotene was 
dissolved in THF at a concentration of 13.4 mg/mL. Cholesterol (recrystallized from EtOH) was 
prepared in deacidified CHCl3 (passed through plug of basic alumina) at a concentration of 5.25 
mg/mL. α-Tocopherol was prepared in deacidified CHCl3 (passed through plug of basic alumina) 
at a concentration of 1.5, 4.5, or 22.4 mg/mL.  
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Preparation of Large Unilamellar Vesicles (LUVs). For α-tocopherol and cholesterol containing 
LUVs, a solution of the small molecule was added to the lipid solution prior to liposome 
formation. For peridinin, astaxanthin, synechoxanthin, chlamydaxanthin (note exceptions), and 
β-carotene containing LUVs, the carotenoid was added directly following liposome formation.5 
To 12x75 mm test tubes was added 150 µL POPC and 50 µL PUFA via Hamilton 
syringe. For α -tocopherol, cholesterol, and chlamydaxanthin (3.4, 4.2, and 6.8% incorporation 
only) containing liposomes, small molecule solution (2-180 µL) was added to the lipid solution. 
The CHCl3 was removed under a gentle stream of nitrogen and the resulting lipid film was stored 
under high vacuum for at least 4 hours prior to use to remove any residual solvent.  
The lipid film was hydrated with 300 µL 150 mM KCl/0.5 mM HEPES pH 7.4 aqueous 
buffer (K buffer) and vortexed vigorously for approximately 2 minutes (until the film was fully 
removed from the sides of the test tube) to form a suspension of multilamellar vesicles (MLVs). 
The resulting lipid suspension was pulled into a Hamilton 1 mL gastight syringe and the syringe 
was placed in an Avanti Polar Lipids Mini-Extruder with a second collection syringe on the 
opposite side. The lipid solution was then passed through a 0.20 µm Whatman polycarbonate 
filter (supported on both sides by a 10 mm Whatman drain disk) 21 times. The resulting LUV 
suspension was collected in the syringe that did not contain the original suspension of MLVs to 
prevent the carryover of MLVs into the LUV solution. All LUV suspensions were added to 
separate clean 12x75 mm test tubes.   
For peridinin, astaxanthin, synechoxanthin, chlamydaxanthin (0.1-2.6, 3.6% 
incorporations), and β-carotene containing liposomes, carotenoid solution (2-100 µL) was added 
dropwise to a gently vortexing suspension of LUVs under a stream of nitrogen. For the control, 
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vehicle was added to a suspension of LUVs in the same manner (volume of vehicle added was 
equivalent to the largest volume used for carotenoid delivery for a given set of liposomes).  
    LUVs were purified by gel size exclusion chromatography with a Sephadex G50-150 
(Sigma-Aldrich) column (1 cm column, 1.0 g unswelled resin, resin swelled with K buffer, 
eluted with K buffer). Purified LUVs were collected in 13x100 mm test tubes, transferred to 20 
mL vials with a syringe for volume determination, and analyzed for total phosphorous 
concentration.  
 
Determination of Phosphorous Content. Determination of total phosphorus was adapted from the 
report of Chen and coworkers.6 10 µL aliquots of the purified LUV suspension were added to 7 
mL vials. To each vial and a vial containing no lipids that was used as a blank, was added 450 
µL of 8.9 M H2SO4 (Fisher Chemical). The four samples were incubated open to ambient 
atmosphere in a 225 °C aluminum heating block for 25 min and then removed to 23 °C and 
cooled for 5 minutes. After cooling, 150 µL of 30% w/v aqueous hydrogen peroxide (Fisher 
Chemical) was added to each sample, and the vials were returned to the 225 °C heating block for 
30 minutes. The samples were then removed to 23 °C and cooled for 5 minutes before the 
addition of 4 mL water. Then 500 µL of 2.5% w/v ammonium molybdate (Sigma-Aldrich) was 
added to each vial and the resulting mixtures were then vortexed briefly and vigorously. 
Subsequently, 500 µL of 10% w/v ascorbic acid (Sigma-Aldrich or Fisher Chemical) was added 
to each vial and the resulting mixtures were then vortexed briefly and vigorously. The vials were 
capped with a PTFE lined cap and then placed in a 100 °C aluminum heating block for 7 
minutes. The samples were removed to 23 °C and cooled for approximately 15 minutes prior to 
analysis by UV/Vis spectroscopy (UV-Vis or plate reader). Total phosphorus concentration was 
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determined by observing the absorbance at 820 nm and comparing this value to a standard curve 
obtained through this method and a phosphorus standard solution (0.65 mM phosphorous as 
KH2PO4, Sigma-Aldrich). LUVs were diluted with K buffer to a final concentration of 1 mM 
total phosphorous, which is equivalent to 1 mM lipid. An aliquot of LUV suspension was 
removed for analysis of small molecule concentration, and the LUVs were stored under N2 
overnight at 4 °C.   
 
Determination of Small Molecule Concentration in LUVs. To HPLC vials were added 100 µL of 
1 mM LUV suspension and 200 µL of 4:1:1 acetone:MeOH:0.2M BHT in EtOH or DMSO. The 
mixtures were vortexed to give clear solutions. The samples were analyzed by analytical HPLC 
(75 or 100 µL injections, see methods above) and the small molecule concentration was 
determined by comparing the peak area to standard curves prepared from small molecule 
solutions of known concentrations. Small molecule content was reported as mol% relative to 
total lipid concentration.  
 
Preparation of MLVs for SSNMR.7 [U-13C]-Astx or [7,7’,15,15’-13C]Peri was dissolved in THF 
and concentration determined by HPLC. Carotenoid solutions were diluted to between 0.5-3.0 
mM in THF. To a 7 mL vial for each required sample was added the carotenoid THF solution 
and solvent removed in vacuo. To each vial was added POPC (673 µL) and in the DOXYL 
containing samples, 5 mol% of the appropriate DOXYL-PC lipid (84 µL) was added. Solvent 
was removed in vacuo and samples placed under high vacuum for ~24 hours. To each vial was 
added H2O (565 µL) and HEPES buffer (18 µL, 10 mM, pH 7.0). The samples were sonicated 
and vortexed to form MLVs. The MLVs were subjected to five freeze/thaw cycles by 
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submerging in liquid N2 and warm water. The samples were then frozen in liquid N2 and water 
removed by lyophilization. The samples were stored as a dry powder at -20 oC under Ar. 
 
MDA-TBA Lipid Peroxidation Time Course Assay. Assay was adapted from Rengel and 
coworkers.5 To 7 mL vials was added 1 mL of the 1 mM LUV suspension.  To each sample was 
added 10 µL of 11 mM CuCl2 (Sigma-Aldrich) in DI H2O.  The vials were capped with a PTFE 
lined cap, gently inverted 5-10x to mix, and incubated in a 37 oC aluminum heating block. At 2.5 
hour intervals for 10 hours (including an initial timepoint directly following CuCl2 addition), the 
vials were gently inverted 3x to mix the suspensions an aliquot was removed from each sample 
and analyzed for MDA content. A 100 µL aliquot was removed from each liposome sample to a 
1.5 mL HPLC vial containing 500 µL of TBA solution (0.4% w/v thiobarbituric acid in 0.1 M 
NaOAc, pH 3.5).  The vials were capped and incubated in a 100 oC aluminum heating block for 
15 minutes.  The samples were removed to 23 oC and cooled for approximately 10 min to 23 oC 
prior to MDA-TBA adduct quantification by HPLC (75 µL injection, see method above). For 
experiments in which carotenoid consumption was concomitantly analyzed, a second aliquot was 
removed from each sample and assayed for small molecule concentration as described above. 
 
Lipid Protection Assay. LUVs containing increasing concentrations of the small molecules 
(astaxanthin, peridinin, synechoxanthin, chlamydaxanthin, and alpha-tocopherol) were prepared 
as described above and subjected to the lipid peroxidation assay. At 2.5 hour intervals, the vials 
were inverted 3x and opened to atmosphere for approximately 10 seconds to simulate the 
experimental conditions for the time course assay. After 10 hours, a 100 µL aliquot was removed 
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from each sample for TBA analysis as described above. The percent protection afforded by the 
small molecule relative to a vehicle control run concurrently was calculated as follows: 
 
The compiled data set for each small molecule was plotted as % incorporation vs. % protection 
and fit in OriginPro using the Exponential function (y = y0 + AeR0x). This function was solved 
for x at y=90 to determine the % incorporation necessary for 90% protection from lipid 
oxidation. Standard error in the fit was propagated to determine standard error in the 90% 
protection value.  
 
PUFA Consumption Assay. LUVs containing astaxanthin and peridinin were prepared as 
described above and subjected to the lipid peroxidation assay. Following CuCl2 addition and 
every 2.5 hours thereafter for 10 hours, 100 mL aliquots of liposome suspension were removed 
to 7 mL vials containing 1.5 mL MeOH and 300 µL 20% v/v HCl in MeOH. Vials were capped 
with PTFE lined caps and heated in a 100 oC aluminum heating block for 45 min. The samples 
were removed to 23 oC and cooled for approximately 10 min prior to the addition of 1 mL brine 
and 1 mL hexanes. The vials were vortexed briefly and vigorously and the hexanes layer 
containing the resulting lipid methyl esters was removed to 7 mL vials. The aqueous layer was 
extracted with hexanes (2 x 1 mL). The combined organic layers were concentrated in a 
lyophilizer jar in vacuo for 45 min to remove all hexanes, redissolved in 300 µL decane, and 
analyzed by GC (7890A Series, Agilent Technologies). The PUFA peak (methyl arachidonate) 
was confirmed via comparison to the known compound (Sigma, catalog number A9298). PUFA 
remaining at each time point was calculated as a percent relative to PUFA at t=0 for the same 
sample. 
% protection = 100− peak area of carotenoid sample









GC Method: Agilent HP-5 capillary column, 2 µL injection, 2:1 split, 250 oC inlet 
temperature, 6 mL/min flow  
Oven program: 170 oC initial temperature, 20 oC/min ramp to 210 oC, 0.5 min hold, 25 
oC/min ramp to 275 oC, 0.5 min hold.     
 
Solution NMR Lipid Diffusion Assay. LUVs containing increasing concentrations of the small 
molecules (astaxanthin, peridinin, and cholesterol) were prepared as described above with the 
following modifications. The lipid films were hydrated with D2O (99.9 atom % D, Sigma-
Aldrich or Cambridge Isotope Laboratories). Sephadex was hydrated and the column eluted with 
D2O. Only the most concentrated 10-14 drops of purified LUV solution were collected from the 
Sephadex size exclusion column (concentrated solution desired for maximized NMR signal). 
Following determination of total phosphorous content as described above, liposomes were 
diluted to a uniform concentration of 3.8 mM with D2O and added to NMR tubes for immediate 
analysis. Experiments were performed at 37 °C using a 750 MHz Varian NMR System Narrow 
Bore spectrometer.  
For each sample, a 1H spectra was recorded and T1 and T2 values were measured for the 
lipid methylene (-CH2) signal. T1 values were measured using standard T1 inversion recovery 
pulse sequence. T2 values were measured using a Carr-Purcell Meiboom-Gill T2 measurement. 
The following big tau (bτ) array was used: bτ = 0.0025, 0.005, 0.01, 0.015, 0.02, 0.03, 0.04, 0.06, 
0.08, 0.1, 0.15, 0.2. After NMR analysis, LUV suspensions were diluted to 1 mM lipid with 
water and analyzed for small molecule concentration as described above.  
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ABTS!+ Electron Transfer Assay. Assay was adapted from Re and co-workers.8 Solutions of 10 
mM 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) (Sigma-
Aldrich) and 4 mM potassium persulfate (Sigma-Aldrich) were prepared in MilliQ water. These 
solutions were mixed in equal volume, resulting in concentrations of 5 mM ABTS and 2 mM 
potassium persulfate. ABTS and potassium persulfate react with a stoichiometry of 2:1, therefore 
this results in incomplete oxidation of ABTS to ABTS!+. This solution was allowed to react 
protected from light for 12-17 hours prior to use.  
An aliquot of the ABTS!+ solution was diluted with ethanol to an absorbance of 0.7±0.02 
at 734 nm (typical dilution was 50 µL ABTS!+ into 4 mL ethanol). The concentration of ABTS!+ 
was calculated utilizing the extinction coefficient 1.6 x104 L mol-1 cm-1.8  
Solutions of astaxanthin and peridinin were prepared in dichloromethane, each at an 
approximate concentration of 2 mM. The resulting carotenoid concentration was quantified by 
HPLC analysis (diluted aliquot of carotenoid solution in DMSO for analysis) and diluted to a 
final concentration of 1.1 mM. The analytical HPLC methods described in General Experimental 
Procedures were utilized. This is the concentration necessary to deliver 1 equivalent carotenoid 
relative to ABTS!+ when 20 µL carotenoid solution is added to 500 µL ABTS!+. 
The UV-Vis (Shimadzu PharmaSpec UV-1700) was baselined at 734 nm. To a quartz 
cuvette fitted with a stopper was added 500 µL ABTS!+ and the absorbance at 734 nm was 
recorded for 30-35 seconds. The cuvette was removed from instrument, a 20 µL aliquot of 
carotenoid solution was added and mixed thoroughly by bubbling air through solution with a 
glass pipette, and the cuvette was replaced in the spectrometer to continue absorbance readings 
for 1 hour.  
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Data points were plotted every 60 seconds from t=30-3570 seconds, normalizing time to 
t=0. Data were fit in OriginPro using the exponential function ExpDec1 (y = y0 + Ae-x/t), where 
output “tau” is the half life (tau = t*ln(2)). For statistical analysis, absorbance at the final 
timepoint for astaxanthin and peridinin were compared by 2-tailed homoscedastic t-test in Excel.    
 
Solution Phase Carotenoid Consumption Assay. Solutions of astaxanthin or peridinin were 
prepared at 500 µM in dichloromethane and diluted to 50 µM with ethanol. Carotenoid 
concentration was then quantified by HPLC analysis (see above for analytical HPLC method) for 
more precise determination and diluted to a final concentration of 33 µM. A solution of CuCl2 
(Sigma-Aldrich) was prepared at 0.82 mM in ethanol. A solution of tBuOOH (70 wt% in H2O, 
Sigma-Aldrich) was prepared at 413 mM in ethanol.  
To a 2 mL glass vial equipped with a stir bar was added 20 µL CuCl2 solution, 20 µL 
tBuOOH solution, and 500 µL carotenoid solution (resulting mixture contains 1 equivalent 
carotenoid, 1 equivalent CuCl2, 500 equivalents tBuOOH). Vial was vortexed to mix and placed 
in a room temperature aluminum block with stirring at 350 RPM. A 50 µL aliquot was 
immediately removed (t=0 timepoint) and worked up to quench the reaction. The aliquot was 
added to a 7 mL vial containing 3 mL EDTA/HEPES buffer (5.5 mM EDTA tetrasodium salt 
hydrate/10 mM HEPES in half-saturated brine, pH adjusted to 7.0 with HCl/NaOH) and 1 mL 
methyl tert-butyl ether and vortexed to mix. The organic layer was transferred to a second 7 mL 
vial and the aqueous layer was extracted with methyl tert-butyl ether (2 x 1 mL). The combined 
organics were extracted with 1 mL EDTA/HEPES buffer and the layers separated. The final 
aqueous wash was extracted with methyl tert-butyl ether (2 x 0.5 mL). All organics were 
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combined. Aliquots were taken at t=0, 10, 20, 30, 45, 60, 90, and 120 minutes and worked up as 
described.  
All combined organics were concentrated in a lyophilizer jar in vacuo for 2-3 hours. Each 
sample was resuspended in 500 µl DMSO and analyzed for carotenoid content by HPLC (35 µL 
injection, methods described above.) Carotenoid remaining at each time point was calculated as a 
percent relative to carotenoid at t=0. For the controls, either the CuCl2 solution or the tBuOOH 
solution was omitted and 20 µL EtOH was added in place of the missing reagent.  
 
Cell Culture Conditions. Primary human umbilical vein endothelial cells (HUVECs, Lonza 
C2517A) were obtained from Lonza and cultured according to manufacturer’s instructions. 
Briefly, cells were maintained in EGM-2 (Lonza CC-3162 BulletKit) comprised of EBM-2 
(Lonza, CC-3156), EGM-2 SingleQuot Kit Suppl. & Growth Factors (CC-4176 containing FBS, 
hydrocortisone, hFGF, VEGF, R3-IGF-1, ascorbic acid, hEGF and heparin; GA-1000 aliquot 
was not used), 50 mg/mL PEN-STREP (Corning, 30-002-Cl), 50 mg/mL gentamycin (Sigma-
Aldrich, G1522) and 2 mg/mL fluconazole (10 mg/mL stock in DMSO, Sigma-Aldrich, F8929). 
Primary HUVECs at passage one were received as frozen stocks and stored in liquid N2 cryo-
storage. One vial from cryo-storage was split into three T-75 flasks with 15 mL warm media per 
flask. The cells were grown to confluence over 5 days changing media the day after seeding and 
every other day there after. The confluent cells were trypsinized (5 mL, 0.25% trypsin EDTA, 
Lonza 17-602E), quenched with 10% FBS (HI, Gibco 16000-036) in HEPES buffered saline 
(Lonza, CC-5024), centrifuged (1500 RPM x 5 min) supernatant removed and cells resuspended 
in warm EGM-2. The cell pellet from each flask was then split 1:4 into T-75 flasks with 15 mL 
warm media/flask. The media was changed the next day and every other day there after until the 
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cells were confluent on day 5. The cells were then trypsinized (5 mL, 0.25% trypsin EDTA), 
spun down (1500 RPM, 5 min) and resuspended in freezing media (10% DMSO Sigma-Aldrich, 
D2438, 10% FBS and 80% EGM-2). The cells were stored at -80 oC for 24 hours and then 
moved into liquid N2 storage. Each experiment used a new cryo-vial of HUVEC cells at passage 
4. 
Monocytes were purchased from Lonza (CD14+ cells, ≥ 40 million cells, catalog # 2W-
400A) and stored in liquid N2 cryo-storage. Immediately prior to use, monocytes were taken out 
of cryo-storage, thawed, diluted in 10 mL ice cold EGM-2 with 10% FBS, centrifuged (300g x 5 
min) and supernatant removed. Monocytes were washed three more times before being counted 
by hemocytometer and diluted to 267,000 cells/mL. The monocyte suspensions were stored in an 
ice bath prior to use in the assay. 
 
Preparation of Carotenoid Solutions for Cellular Assays. Fresh DMSO stock solutions of 
each small molecule (peridinin, astaxanthin, a-tocopherol and OH-pen) were prepared (1 – 2.5 
mM) and concentrations of carotenoid solutions (peridinin and astaxanthin) were checked by 
HPLC (average of 3 runs) prior to each experiment. DMSO stock solutions were then added to 
EGM-2 (0.1 – 0.5% DMSO) or basal media (0.1 – 0.5%) as required at the appropriate final 
concentration. 
 
Antilipoperoxidant Assay in Primary HUVECs. HUVECs were taken out of cryo-storage and 
seeded into two T-75 flasks with 15 mL warm media. The media was changed the next day and 
then every other day there after until the cells were confluent on days 4 or 5. The cells were 
trypsinized (5 mL, 0.25% trypsin EDTA), trypsin quenched with 10% FBS in HEPES buffered 
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saline, centrifuged (1500 RPM, 5 min), supernatant removed and cells resuspended in warm 
EGM-2. The cells were counted by hemocytometer and diluted to between 35,000 and 50,000 
cells/mL. The cells were seeded onto 24-well plates with 1 mL cell suspension per well and cells 
incubated at 37 oC. All experiments were run with 3 – 6 wells per condition per time point. The 
cells were allowed to attach for 24 – 36 hours, media aspirated and replaced with media 
containing either DMSO alone or the appropriate small molecule. HUVECs were incubated at 37 
oC for 12 hours with the appropriate small molecule. Lipid oxidation was initiated by switching 
to basal media (EBM-2, Lonza CC-3156 supplemented with hydrocortisone, hFGF, VEGF, R3-
IGF-1, hEGF and heparin from EGM-2 SingleQuot Kit Suppl. & Growth Factors; FBS, ascorbic 
acid and antibiotics were not added). HUVECs were washed (1 x 0.75 mL) with basal media. In 
the dose-response assay (Figure 2-X), basal media containing the appropriate small molecule 
was added to the HUVECs to initiate lipid peroxidation. In this assay, time points were taken at 
initiation of lipid peroxidation and again after 2 hours. In the time course assay (Figure 2-X), 
basal media without small molecule was added to the HUVECs to initiate lipid peroxidation. In 
this assay, time points were taken every 30 minutes for 2 hours. Identical 24-well plates were 
setup in parallel to measure cell counts (see Cell Counting Workup). 
 
MDA Workup. For each well, the media was transferred to a 1.7 mL eppendorf tube containing 
20 µL 0.2 M BHT in EtOH. The cells were scraped (United Biosystems, MCS-200) and the well 
washed with the initially removed media, which was then returned to the eppendorf tube. The 
well was washed a final time with 200 mL PBS which was added to the same eppendorf. The 
media/PBS mixture in the tube was flash frozen in liquid N2 and stored at -80 oC until the end of 
the experiment. All samples from a single time point were then thawed (37 oC for 2 minutes) and 
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800 µL added to an HPLC vial containing 10 µL 0.25 M trichloroacetic acid, 50 µL acetate 
buffer (pH 3.5, 2 M) and 20 µL 1 M thiobarbituric acid in DMSO. The vial was capped, vortexed 
and heated in an aluminum heat block at 100 oC for 15 minutes. The samples were cooled to 
room temperature, filtered through a 0.2 µm PTFE syringe filter (Fisher, 9720002) and MDA-
TBA adduct quantified by HPLC (100 µL injection, 67% KH2PO4, 20% MeOH, 13% MeCN, 1.5 
mL/min isocratic, Eclipse XDB-C18, 5 mm, 4.6 x 150 mm column Agilent, 993967-902). Lipid 
protection (%) was calculated as before (see Lipid Protection Assay). 
 
Cell Counting Workup. Media was aspirated, cells washed with HEPES buffered saline (500 
µL) and trypsin (250 µL, 0.25 mg/mL with EDTA) was added. Cells were trypsinized at 37 oC 
for 5 – 7 minutes. The trypsizined cell suspension was added to a BD TrucountTM Tubes (catalog 
# 340334) containing trypsin neutralizing solution (300 µL, 10% FBS in HEPES buffered 
saline). Trypsin protocol was repeated and cell suspension added to the same BD TrucountTM 
Tube. Each well was then washed with trypsin neutralizing solution (2 x 300 µL, 10% FBS in 
HEPES buffered saline) with each wash being added to the same BD Trucount Tube. Cell counts 
were immediately measured on a BD LSR II Flow Cytometry Analyzer recording 3000 total 
bead events per tube.  
 
Monocyte Binding Assay.  
Media Used in This Experiment:  
Growth Media – EGM-2 supplemented with CC-4176: FBS, hydrocortisone, hFGF, VEGF, R3-
IGF-1, ascorbic acid, hEGF and heparin; GA-1000 aliquot was not used. 
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OxPUFA Media – growth media as above supplemented with 100 µg/mL PUFA (1-stearoyl-2-
arachidonoyl-sn-glycero-3-phosphocholine) oxidized under a gentle stream of air for 48 hours 
and delivered in 0.1% DMSO. 
Basal Media – (EGM-2 supplemented with CC-4176: hydrocortisone, hFGF, VEGF, R3-IGF-1, 
hEGF and heparin; FBS, ascorbic acid and GA-1000 aliquots were not used) 
High-FBS EGM-2 Media – EGM-2 supplemented with 10% FBS and CC-4176: hydrocortisone, 
hFGF, VEGF, R3-IGF-1, ascorbic acid, hEGF and heparin; GA-1000 aliquot was not used 
HUVECs were prepared as above (see Antilipoperoxidant Assay in Primary HUVECs) 
and seeded into 48-well plates with a 50,000 cell/mL suspension in EGM-2 and 0.5 mL per well. 
The HUVECs were allowed to attach for 36 hours and then incubated with either DMSO, 2 µM 
astaxanthin or 2 µM peridinin for 12 hours as before (see Antilipoperoxidant Assay in Primary 
HUVECs). The cells were washed (1 x 0.75 mL) with either growth, OxPUFA media or basal 
media without added carotenoid and the appropriate media was added to start the experiment. 
The were incubated at 37 oC for 2 hours and the cells were washed (3 x 0.5 mL) high-FBS EGM-
2 and then monocytes (0.75 mL of 267,000 cell/mL suspension at 0 oC) were added to each well. 
The cells were incubated at 37 oC for 20 minutes, washed with high-FBS EGM-2 (3 x 0.5 mL) 
and fixed at 23 oC with 500 µL of 10% neutral buffered formalin (Sigma-Aldrich, HT5011) for 1 
hour. Finally, the cells were washed with PBS (3 x 0.5 mL) and imaged at 10x magnification on 
a phase contrast microscope. Five images of fully confluent cells from different sections of each 
well were taken for monocyte counts. Each image was given a number, randomized (by a second 
person) and adherent monocytes were counted in each image. The monocytes counted in each of 
the five images were averaged to give a single number for each well. This experiment was run 
with 24 wells per condition.  
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Biosynthesis of [U-13C]Astx. [U-13C]Astx was prepared from the red yeast Xanthophyllomyces 
dendrorhous (strain UBV-AX2, ATCC strain #74219). The ampule of X. dedrorhous obtained 
from ATCC was grown to confluency in custom yeast media (see below). Back stocks were 
prepared via the addition of 0.5 mL yeast in media and 0.5 mL of 40% glycerol to 2 mL 
cryovials. Vials were frozen and stored at -80 oC.  
 Fermentation: To six baffled flasks (500 mL) was added 100 mL media, 1 mL of a 40% 
[U-13C] glucose solution and 1 mL of thawed yeast back stock. The flasks were shaken at 20 oC, 
250 RPM under continuous light for 7 days. Yeast cultures were fed once per day with 1 mL of a 
40% [U-13C]glucose solution for the first 5 days. On the 7th day, the cultures were spun down 
(3000g x 10 min), supernatant discarded, and the pellets combined into 6 50 mL conical tubes. 
The yeast pellets were washed with water (3 x 40 mL), frozen, and lyophilized to yield a dry red 
powder.  
 Isolation: To each conical tube was added 3 g of glass beads (Sigma-Aldrich, 425-600 
µm acid-washed) and 25 mL of warm DMSO (55 oC). The tubes were vortexed (3 x 30 sec.), 
centrifuged (3000g x 5 min) and supernatant removed. The extraction was repeated 5 – 7 times 
until no significant color remained in the supernatant. The supernatants from all the extractions 
were combined and divided into three aliquots. The first aliquot was added to a 4 L separatory 
funnel containing 2 L of brine and was extracted with 500 mL EtOAc. The extraction was 
repeated with 500 mL EtOAc 8 -12 times until no significant color remained in the aqueous 
layer. The combined organic layers were dried with Na2SO4 and solvent removed in vacuo to 
give a red oil. This procedure was repeated with the remaining DMSO extracts.  
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 Purification: The crude [U-13C]Astx was combined and half the material was loaded onto 
Celite, purified by reverse phase chromatography on C18 silica gel (12g) (90:10 " 100:0 
MeOH:H2O) and solvent removed in vacuo to give a red solid. Purification was repeated on the 
second half of the crude [U-13C]Astx. The combined [U-13C]Astx was dissolved in DMSO (15 
mL) and purified by preparative HPLC to give 15.8 mg of red solid. This red solid was dissolved 
in DMSO and repurified by semi-prep HPLC to give 8.5 mg of pure [U-13C]Astx (0.0142 mmols, 
14.2 mg/mL) with 65% 13C incorporation as determined by 1H NMR. 
 
Preparative HPLC Method: 
Column: Sunfire Prep C18, 5 mm, 30 x 150 mm 
Flow Rate: 25 mL/min. 
Solvent A: 92.5:7.5 MeOH:H2O 
Solvent B: Acetone 
Method: 100% A (0 – 14 min.), 100% A " 100% B (14 – 14.5 min.), 100% B (14.5 – 19.5 min.) 
Elution Time: 12.9 min. 
 
Semi-preparative HPLC Method: 
Column: Sunfire Prep C18, 5 mm, 10 x 250 mm 
Flow Rate: 25 mL/min. 
Solvent: 95:5 MeOH:H2O 




Yeast Extract (22.5 g), NH4SO4 (7.5 g), KH2PO4 (4.5 g), MgSO4 (1.5 g) inositol (195 mg) 
pyridoxine!HCl (105 mg), ZnSO4 (45 mg), thiamine!HCl (30 mg) and Cu pantothenate (24 mg) 
were combined in a 2 liter culture bottle and H2O was added to a total volume of 1.5 L. To the 
liquid media was added FeNH4SO4 (15 mg, 0.750 mL of a 200 mg/mL stock solution in H2O), 
CuSO4 (3 mg, 0.150 mL of a 20 mg/mL stock solution) and biotin (0.15 mg, 0.075 mL of a 2 
mg/mL stock solution). The media was set to pH 5.5 with 1M citric acid and 15% KOH. The 
media was autoclaved prior to use. 
 
Solid-State NMR Methods. 
SSNMR Sample Packing  
Samples were then packed into 3.2 mm diameter SSNMR rotors (Agilent Technologies, 
Inc.) and rehydrated with MilliQ water (~6 µl). Hydration of 21-30% (by 1H NMR) was 
maintained by Kel-F and rubber spacers.  
SSNMR Experiments 
 All NMR experiments were performed on a 600 MHz InfinityPlus spectrometer (Agilent 
Technologies, Inc.) with a 3.2 mm Agilent Balun 1H-13C-15N MAS probe. Unless otherwise 
noted, all experiments were acquired at 12.5 kHz MAS and at a VT temperature set point of 20 
oC, except for 2D 13C -13C and 3D 13C-13C-13C correlation experiments which were acquired at a 
VT temperature of 0 oC. SPINAL-64 1H decoupling was employed during acquisition and 
evolution periods with ~80 kHz field strength. Tangent ramped cross polarization was utilized 
for multidimensional experiments, while 1D spectra, including T1 measurements, were acquired 
using direct 13C polarization. Chemical shifts were externally referenced to the downfield 13C 
peak of adamantane (40.48 relative to DSS).  
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 Processing and integrations of 1D spectra, including those for T1 measurements, were 
performed with Varian Spinsight software 4.3.2, and spectra were subsequently visualized using 
Mnova 8.1 software (Mestrelab Research SL). Multidimensional spectra were processed in 
NMRPipe and peaks were picked using the Gaussian fit method in Sparky. In all cases data was 
processed using back linear prediction in the direct dimension and Lorentzian-to-Gaussian 
apodization in all dimensions prior to zero filling and Fourier transformation.  
Assignments and 1D Spectra 
 13C-13C POST-C7 spectra with either 28, 42, or 56 post-cycles were taken of the 
carotenoid containing samples to obtain one- and two-bond correlations. For 3D 13C-13C-13C 
correlation experiments, SPC7 mixing for 13C though-bond polarization transfer was employed 
during the first mixing period (qspcn of 28) of and DARR mixing was employed during the 
second period. Pulse delays of 1.5 and 0.8 s were employed for 2D and 3D spectra, respectively. 
With the exception of double-quantum-filtered spectra, which used a pulse delay of 7 s. 1D 
spectra were obtained with a pulse delay of 25 s to achieve nearly complete relaxation of all 
spins.  
PRE Measurements 
13C T1 values were measured using a standard T1 inversion recovery pulse sequence, with 
a pulse delay of 7 s and 20 randomized delay times (τ) of 0.001, 0.01, 0.015, 0.02, 0.03, 0.05, 
0.075, 0.1, 0.15, 0.25, 0.4, 0.6, 0.9, 1.2, 2, 3, 4, 6, 8, and 10 s. Data was collected in 8 replicates 
for statistical analysis, and each time point was averaged over 96 scans with 8 dummy scans. 
POPC peak integration boundaries were set as the linewidth at half height. The entirety of Astx 
peaks were integrated to avoid bias towards one population over another. The polyene region of 
the spectrum was integrated in two large integrations (“a” and “b”) because of insufficient 
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resolution to isolate full sets of four peaks for a given carbon. T1 curves were fit using the 
interior-point method in Matlab R2014a (The MathWorks, Inc.), or the generalized reduced 
gradient method in the Solver function in Excel (Microsoft Office 2011) in the case of global fits 
of the ratio of Astx populations, I0,A/I0,B. POPC relaxation curves were fit to a single exponential 
decay of the form:  
!!(1− (2− !!!!!!"!#$)!!!!!)       (1) 
where τ is the delay time, R1 = 1/T1 is the longitudinal relaxation rate, I0 is the integration 
intensity at full relaxation, and tcycle is the time in between acquisitions, given by the sum of the 
acquisition and pulse delay, 7.03072 s in all T1 experiments. Astx relaxation curves were fit to a 
double exponential decay of the form:  
!!,! 1− 2− !!!!,!!!"!#$ !!!!,!! + !!,!(1− (2− !!!!,!!!"!#$)!!!!,!!)  (2) 
where subscripts A and B refer to the major and minor components of the fit. Longitudinal 13C 
PREs were determined by calculating the difference in R1 values in the presence and absence of 
5% 16-DOXYL-POPC. We report as uncertainty the propagated standard error in R1 fits across 8 
replicate datasets. We report as uncertainty of I0,A/I0,B either the propagated standard error of this 
parameter across global fits to 8 replicate datasets, or the standard error across multiple 
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Cell Counts at 2h 
Figure 2-21. β-Carotene functions as a prolipoperoxidant in chemically-defined liposomes as 
indicated by increased concentrations of the PUFA decomposition product MDA relative to vehicle.  
Figure 2-22. Extended lipid protection curve for α-tocopherol in liposomes. The small molecule is 
unable to reach 90% lipid protection at concentrations up to 37 mol% relative to lipid.     
Figure 2-23. No significant difference in HUVEC count is observed at either 0 or 2 hours in the lipid 
peroxidation assay, indicating no small molecule toxicity and that differences in MDA formation are 





































































































Figure 2-25. ABTS!+ undergoes minimal degradation in the absence of carotenoid.        
Figure 2-26. Astaxanthin and peridinin undergo no significant reactivity with tBuOOH alone. 
Treatment with CuCl2 alone results in no peridinin loss while astaxanthin undergoes 20% degradation.          
Figure 2-24. Lipid protection curve for the N-oxide antilipoperoxidant OH-pen in HUVECs. OH-pen 


































































































































































































































































Figure 2-27. Spin diffusion to water and POPC lipid for all 13C-peridinin carbons.          
Figure 2-28. Full DOXYL PRE series. The observed trends for the 7/7’ and 15/15’ 13C-peridinin 
labels are very similar.           
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III. SYNTHESIS OF 13C4 PERIDININ  
 
 
13C Allylic alcohol 2.6. To a flame-dried 100 mL Schlenk flask equipped with a stir bar was 
added vinyl iodide 2.510 (3.10 g, 8.2 mmol, 1 equiv.). The flask was vac-filled with argon (x 3). 
THF (9.3 mL) was added via syringe and the solution was cooled to -78 °C in a dry 
ice/isopropanol bath with stirring for 20 minutes. To this solution was added tert-butyllithium 
(1.7 M in pentane, 11 mL, 18.7 mmol, 2.3 equiv.) dropwise over 30 minutes. The resulting 
solution was stirred at -78 °C for 10 minutes. To a flame-dried 20 mL vial was added 13C 
paraformaldehyde 99 atom % (0.51 g, 16.3 mmol, 2 equiv.). The flask was vac-filled with argon 
(x 3) and THF (4 mL) was added to form a suspension. The paraformaldehyde suspension was 
added via syringe to the prepared solution of lithiated vinyl iodide, rinsing the vial with an 
additional 4 mL THF. The reaction was stirred at -78 °C for 1 hour, then allowed to gradually 
warm to room temperature and stir for another 17 hours under argon. The reaction was quenched 
with H2O (20 mL) and transferred to a separatory funnel containing brine (30 mL) and Et2O (30 
mL). The layers were separated and the aqueous layer was extracted with Et2O (3 x 30 mL). The 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo to afford a 
clear, colorless oil. The crude material was purified via silica gel chromatography 
(hexanes:EtOAc 85:15) to afford the product 2.6 as a white solid (1.92 g, 83% yield).  
 
TLC (hexanes:EtOAc 4:1)  













1H-NMR (500 MHz, CDCl3) 
δ 4.17 (dd, J = 142.3, 11.5, Hz, 1H), 4.09 (dd, J = 141.0, 11.5 Hz, 1H), 3.95-3.90 (m, 
1H), 2.18 (m, 1H), 2.05 (dd, J = 17.1, 9.3 Hz, 1H), 1.76 (s, 3H), 1.64 (m, 1H), 1.46 (t, J = 
12.0 Hz, 1H), 1.10 (s, 3H), 1.05 (s, 3H), 0.90 (s, 9H), 0.07 (s, 6H) 
 
13C-NMR (125 MHz, CDCl3) 




Calculated for 12C1513CH33O2Si (M+H)+: 286.2283  
Found:      286.2285  
 
 
13C Epoxy alcohol 2.7. To a flame-dried 40 mL vial equipped with a stirbar was added (-)-
diethyl D-tartrate (1.05 mL, 6.13 mmol, 1.2 equiv.). The vial was sealed with a septum cap and 
vac-filled with argon (x 3). CH2Cl2 (8 mL) was added via syringe and the vial was cooled to -20 
°C using an immersion cooler. To the solution was added Ti(OiPr)4 (1.5 mL, 5.11 mmol, 1 
equiv.) which was maintained at -20 °C with stirring for 20 minutes. tBuOOH (5 M in decane, 
2.0 mL, 10.22 mmol, 2 equiv.) was then added and the resulting solution was stirred at -20 °C for 













equiv) and a stir bar was added activated 4 Å molecular sieves and vac-filled with argon (x 3). 
CH2Cl2 (11 mL) was added via syringe and the solution was cooled to -20 °C. The Ti(OiPr)4 
solution was cannulated to the flask containing the allylic alcohol over 7 minutes, and the 
resulting reaction mixture was maintained at -20 °C with stirring for 12.5 hours. The reaction 
was quenched with the addition of Et2O (7.5 mL), 30% aq NaOH (0.3 mL), and brine (0.3 mL) 
and allowed to warm to room temperature with stirring. Celite and Na2SO4 were added and the 
resulting slurry was filtered over a pad of Celite with Et2O. The crude material was adsorbed 
onto Celite from an Et2O slurry and purified by silica gel chromatography (hexanes:EtOAc 
90:10) to yield the product 2.7 (1.44 g, 94% yield, 7:1 dr) 
 
TLC (hexanes:EtOAc 4:1)  
 Rf = 0.37, stained by KMnO4  
 
1H-NMR (500 MHz, CDCl3) 
δ 3.85 (dd, J = 144.5, 11.5 Hz, 1H), 3.79 (m, 1H), 3.72 (dd, J = 143.0, 11.5 Hz, 1H), 2.22 
(dd, J = 14.5, 5.0 Hz, 1H), 1.63 (dd, J = 14.5, 8.5 Hz, 1H), 1.44 (m, 1H), 1.40 (s, 3H), 
1.24 (m, 1H), 1.13 (s, 3H), 1.06 (s, 3H), 0.87 (s, 9H), 0.04 (s, 3H), 0.04 (s, 3H) 
 
13C-NMR (125 MHz, CDCl3)  





Calculated for 12C1513CH33O3Si (M+H)+: 302.2233  
Found:      302.2234  
 
 
13C Aldehyde 2.8. To a flame-dried 50 mL Schlenk flask equipped with a stir bar and purged 
with argon was added oxalyl chloride (0.35 mL, 4.13 mmol, 1.4 equiv.) and CH2Cl2 (10 mL). 
The solution was cooled to -78 °C in a dry ice/isopropanol bath. DMSO (0.5 mL, 7.08 mmol, 2.4 
equiv.) was added and the solution was stirred at -78 °C for 5 minutes. A solution of epoxy 
alcohol 2.7 (0.89 g, 2.95 mmol, 1.0 equiv.) in CH2Cl2 (9.5 mL) was added via syringe and the 
resulting mixture was stirred for 15 minutes. NEt3 (2.7 mL, 19.5 mmol, 6.6 equiv.) was added 
via syringe. The reaction was stirred at -78 °C for 10 minutes, after which the cooling bath was 
removed and the reaction was allowed to warm to room temperature. After 1 hour, the reaction 
was transferred to a separatory funnel containing H2O (20 mL) and CH2Cl2 (20 mL). The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The crude material 
was purified via silica gel chromatography (3.5% EtOAc in hexanes) to afford the product 2.8 
































13C Alkyne 2.9.  To a flame-dried 100 mL Schlenk flask purged with argon was added 
diisopropylamine (0.5 mL, 3.5 mmol, 1.4 equiv.) and THF (20 mL). The solution was cooled to 
0 °C in an ice bath. n-Butyllithium (2.5 M in hexanes, 1.4 mL, 3.5 mmol, 1.4 equiv.) was added 
dropwise and the resulting solution stirred for 30 minutes. The 0 °C bath was replaced with a -78 
°C dry ice/isopropanol bath and the solution was allowed to cool with stirring for 10 minutes. 
Trimethylsilyldiazomethane (2 M in Et2O, 1.8 mL, 3.5 mmol, 1.4 equiv.) was added and the 
solution was stirred for 30 minutes. A solution of aldehyde 2.8 (0.75 g, 2.5 mmol, 1 equiv.) in 
THF (6.2 mL) was added to the reaction. The mixture was stirred at -78 °C for 1 hour, after 
which the cold bath was removed and the reaction was stirred at room temperature for an 
additional 2 hours. The reaction was again cooled to 0 °C, quenched with 15% acetic acid in 
EtOAc (7 mL), and allowed to warm to room temperature with stirring over 15 minutes. The 
solution was transferred to a separatory funnel with H2O (30 mL) and Et2O (30 mL). The layers 
were separated and the aqueous layer was extracted with Et2O (2 x 30 mL). The combined 
organic layers were washed with brine (2 x 30 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude material was purified via silica gel chromatography (3% 
EtOAc in hexanes) to afford the product 2.9 (0.48 g, 66% yield). Note: We did not observe a 
peak in the 13C NMR for the quaternary carbon adjacent to the 13C labeled carbon.  
 
TLC (hexanes:EtOAc 9:1)  
 Rf = 0.66, stained by KMnO4  
 
1H-NMR (500 MHz, CDCl3) 
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δ 3.77 (m, 1H), 2.39 (d, J = 49.5 Hz, 1H), 2.21 (dd, J = 14.5, 4.7 Hz, 1H), 1.65 (dd, J = 
14.5, 8.0 Hz, 1H), 1.49 (s, 3H), 1.48-1.45 (m, 1H), 1.25 (s, 3H), 1.23-1.16 (m, 1H), 1.10 
(s, 3H), 0.86 (s, 9H), 0.03 (s, 3H), 0.03 (s, 3H)   
 
13C-NMR (125 MHz, CDCl3)  
δ 81.0, 74.0 (d, J = 173.6 Hz), 66.1, 64.4, 45.7, 40.4, 34.0, 29.7, 26.0, 25.7, 21.8, 18.2, -
4.6, -4.6    
 
HRMS (EI+) 
Calculated for 12C1613CH30O2Si (M)+: 295.2049  
Found:      295.2045  
 
 
13C Pinacol boronic ester 2.10.  To a flame dried 7 mL vial equipped with a stir bar was added 
alkyne 2.9 (416.5 mg, 1.4 mmol, 1 equiv.), sealed with a septum cap, purged with argon, and 
taken into the glovebox. To the vial was added dicyclohexylborane (27.4 mg, 0.154 mmol, 0.11 
equiv.) sealed, and removed from the glovebox. To the reaction vial was added pinacolborane 
(0.3 mL, 2.1 mmol, 1.5 equiv.) via syringe to yield a yellow/white slurry. The vial was sealed 
with Teflon tape and parafilm and the reaction was allowed to stir 14 hours at room temperature. 
The resulting solid was dissolved in Et2O, adsorbed onto Celite, and purified by silica gel 


















TLC (95:5 hexanes:EtOAc)  
 Rf = 0.50, stained with cerium ammonium molybdate  
 
1H-NMR (500 MHz, CDCl3)  
δ 6.79 (dd, J = 155.6, 17.9 Hz, 1H), 5.63 (dd, J = 17.9, 7.2 Hz, 1H), 3.81 (m, 1H), 2.19, 
(ddd, J = 14.6, 5.1, 1.7 Hz, 1H), 1.59 (dd, J = 14.5, 8.2 Hz, 1H), 1.45 (ddd, J = 13.1, 3.4, 
1.7, 1H), 1.24 (s, 12H), 1.22-1.15 (m, 1H), 1.12 (s, 3H), 1.11 (s, 3H), 0.90 (s, 3H), 0.83 
(s, 9H), 0.00 (s, 3H), 0.00 (s, 3H)    
   
13C-NMR (125 MHz, CDCl3)  
δ 148.2, 83.3, 71.2 (d, J = 53.3 Hz), 66.5, 64.8, 47.2, 41.4, 34.9, 29.6, 26.0, 25.0, 24.9, 
20.3, 18.2, -4.6, -4.6  
 
HRMS (ES+) 
Calculated for 12C2213CH44BO4Si (M+H)+:  424.3135  
Found:       424.3139  
 
 
13C BB1 MIDA boronate. Pinacol boronic ester 2.10 (185 mg, 0.44 mmol, 1 equiv.) was 
concentrated in a 40 mL vial. To the vial was added methyliminodiacetic acid (387 mg, 2.63 
mmol, 6 equiv.) and DMSO (4.4 mL). The vial was sealed with a PTFE-lined cap, placed in a 65 






















block and allowed to cool to room temperature. The reaction mixture was transferred to a 
separatory funnel with H2O (100 mL) and EtOAc (40 mL). The layers were separated and the 
aqueous layer was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed 
with half-saturated brine (2 x 30 mL), dried over MgSO4, filtered, and concentrated in vacuo. 
The crude material was adsorbed onto Celite from an acetone slurry and purified via silica gel 
chromatography (Et2O to 3:2 acetone:Et2O) to afford the product 13C BB1 as a white solid (86 
mg, 44% yield) with recovered pinacol boronic ester 2.10 starting material (84 mg).  
 
TLC (Et2O:MeCN 4:1)  
 Rf = 0.49, stained with KMnO4  
 
1H-NMR (500 MHz, d6-acetone) 
δ 6.38 (dd, J = 154.0, 17.5 Hz, 1H), 5.71 (dd, J = 18.0, 7.0 Hz, 1H), 4.23 (dd, J = 17.0, 
2.0 Hz, 2H), 4.06 (dd, J = 17.0, 4.5 Hz, 2H), 3.87 (m, 1H), 3.02 (s, 3H), 2.21 (ddd, J = 
14.5, 5.0, 1.5 Hz, 1H), 1.66 (dd, J = 8.0, 14.5 Hz, 1H), 1.49 (ddd, J = 12.5, 3.0, 1.5 Hz, 
1H), 1.20-1.28 (m, 1H), 1.15 (s, 3H), 1.14 (s, 3H), 0.93 (s, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 
0.05 (s, 3H) 
 
13C-NMR (125 MHz, d6-acetone)  
δ 169.0, 140.8, 118.6 (d, J = 70.4 Hz), 71.4 (d, J = 53.8 Hz), 66.5, 65.7, 62.4, 47.9, 47.6, 




Calculated for 12C2113CH39BNO6Si (M+H)+:  453.2673  




13C Alkynyl alcohol deprotection 2.11 To a flame-dried 7 mL vial equipped with a stir bar and 
charged with alkyne 2.9 (209 mg, 0.71 mmols, 1.0 equiv) was added THF (1.4 mL) and TBAF 
(1M in THF, 1.4 mL, 1.4 mmols, 2.0 equiv). The vial was stirred for 24 hours at room 
temperature. To the vial was added saturated NaHCO3 (1 mL) and the reaction mixture was 
transferred to a separatory funnel containing NaHCO3 (30 mL) and Et2O (30 mL). The aqueous 
layer was extracted with Et2O (3 x 20 mL), organics combined and washed with brine (2 x 20 
mL), dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by 
silica gel chromatography (80:20 hexanes:EtOAc) to give 2.11 a white solid (102 mg, 79% 
yield). Note: We did not observe a peak in the 13C NMR for the quaternary carbon adjacent to 
the 13C labeled carbon. 
 
1H-NMR (500 MHz, CDCl3) 
δ 3.80 (m, 1H), 2.40 (d, J = 49.6 Hz, 1H), 2.33 (ddd, J = 14.5, 5.1, 1.8 Hz, 1H), 1.63 (dd, 
J = 14.3, 8.7 Hz, 1H), 1.60-1.56 (m, 1H), 1.51 (s, 3H), 1.26 (s, 3H), 1.24-1.18 (m, 1H), 
1.11 (s, 3H)  
 















δ 80.6, 74.2 (d, J = 173.8 Hz), 66.7, 63.8, 45.9, 39.9, 34.2, 29.9, 25.5, 21.5  
 
HRMS (EI+) 
Calculated for 12C1013CH16O2 (M)+: 181.11839   
Found:     181.11886  
 
 
13C Iodoallene 2.12. A flame-dried 10 mL Schlenk flask equipped with a stir bar and charged 
with 2.11 (102 mg, 0.562 mmols, 1.0 equiv) was cooled in an IPA bath held at -12 oC via cryo-
cool. To the flask was added Et2O (3.25 mL) followed by CuI (105 mg, 0.55 mmols, 0.98 equiv) 
and NH4I (39 mg, 0.27 mmols, 0.48 equiv) under a stream of Ar and HI (57% solution, distilled 
and stabilized, 0.11 mL, 0.83 mmols, 1.5 equiv) was added. The reaction was stirred at -10 to -12 
oC for 1 hour and 45 minutes. While at -12 to -10 oC, to the flask was added 1.5 mL NH4OH and 
1.5 mL saturated NH4Cl. The blue reaction mixture was then poured into a separatory funnel 
containing brine (30 mL) and Et2O (30 mL). The organic layer was extracted with Et2O (3 x 20 
mL), organics combined, washed with brine (2 x 20 mL), dried over MgSO4, filtered and solvent 
removed in vacuo. The crude material was purified by silica gel chromatography (70:30 " 50:50 
hexanes:EtOAc) to give 2.12 as a white solid (112 mg, 65% yield). Note: Product contained 
10% of the inseparable protodehalogenated byproduct which carried forward to the next 
reaction. 
 















 Rf = 0.41, visualized by short wave UV  
 
1H-NMR (500 MHz, CDCl3) 
δ 5.74 (d, J = 5.6 Hz, 1H), 4.29-4.23 (m, 1H), 2.20 (ddd, J = 13.1, 4.2, 2.3 Hz, 1H), 1.89 
(ddd, J = 12.6, 4.2, 2.4 Hz, 1H), 1.41 (s, 3H), 1.39-1.29 (m, 2H), 1.31 (s, 3H), 1.15 (s, 
3H) 
 
13C-NMR (125 MHz, CDCl3) 




Calculated for 12C1013CH17O2I (M)+: 309.0307   
Found:     309.0315  
 
 
13C Allene acetate protection 2.13. To a flame-dried 7 mL vial equipped with a stir bar and 
charged with 13C allene 2.12 (110 mg, 0.356 mmols, 1.0 equiv) was added pyridine (1.2 mL, 
freshly distilled) and acetic anhydride (0.17 mL, 1.8 mmols, 5.0 equiv.). The reaction was stirred 
at room temperature for 10 hours. The reaction was poured into a separatory funnel containing 
Et2O (10 mL) and saturated NaHCO3 (10 mL) and extracted with Et2O (2 x 10 mL). The 


















material was purified by silica gel chromatography (80:20 to 70:30 hexanes:EtOAc) to give 2.13 
as a white solid (88.5 mg, 71% yield).  
 
TLC (60:40 hexanes:EtOAc) 
 Rf = 0.53, stained by KMnO4  
 
1H-NMR (500 MHz, CDCl3) 
δ 5.75 (d, J = 5.6 Hz, 1H), 5.29 (m, 1H), 2.21 (ddd, J = 13.0, 4.3, 2.3 Hz, 1H), 2.01 (s, 
3H), 1.90 (ddd, J = 12.4, 4.3, 2.3 Hz, 1H), 1.50-1.33 (m, 2H), 1.40 (s, 3H), 1.34 (s, 3H), 
1.13 (s, 3H)  
 
13C-NMR (125 MHz, CDCl3)  
δ 201.8, 170.6, 119.2 (d, J = 102.5 Hz), 71.7, 67.7, 44.8, 44.8, 38.6 (d, J = 110.6), 35.4, 
31.2, 30.7, 29.8, 21.6  
 
HRMS (EI+) 
Calculated for 12C1213CH19IO3 (M)+: 351.0413   






















13C BB4 TMS protection. To a flame-dried 7 mL vial charged with 2.13 (85 mg, 0.242 mmols, 
1.0 equiv) was added methylene chloride (1.2 mL), 2,6-lutidine (freshly distilled, 0.34 mL). The 
vial was cooled to 0 oC and TMSOTf (0.35 mL, 1.93 mmols, 8.0 equiv) was added dropwise. 
The reaction was allowed to warm to room temperature and stirred for 2 hours. The reaction was 
cooled to 0 oC and H2O (1 mL) was added dropwise. The reaction was poured into a separatory 
funnel containing Et2O (10 mL) and brine (10 mL) and extracted with Et2O (3 x 10 mL). The 
combined organics were washed with brine (2 x 10 mL), dried with MgSO4, filtered and solvent 
removed in vacuo. The crude material was purified by reverse phase chromatography on C18 
silica gel (40:60 to 0:100 H2O:MeCN) to give 13C BB4 as an off-white solid (68 mg, 66% yield).  
 
TLC (hexanes:Et2O 1:1) 
 Rf = 0.79, visualized by short wave UV 
 
1H-NMR (500 MHz, CDCl3) 
δ 5.68 (d, J = 5.6 Hz, 1H), 5.26 (m, 1H), 2.19 (ddd, J = 12.6, 4.1, 2.3 Hz, 1H), 2.01 (s, 
3H), 1.90 (ddd, J = 12.3, 4.2, 2.3 Hz, 1H), 1.42 (s, 3H), 1.41-1.30 (m, 2H), 1.30 (s, 3H), 
1.11 (s, 3H), 0.09 (s, 9H) 
 
13C-NMR (125 MHz, CDCl3)  
δ 201.8, 170.5, 119.1 (d, J = 103.0 Hz), 73.9, 68.0, 46.9, 44.9, 37.9 (d, J = 110.8 Hz), 




Calculated for 12C1513CH27IO3Si (M)+: 423.0808   
Found:      423.0791 
  
 
13C GeEt3/TMS-alkyne 2.15. A flame dried 25 mL Schlenk flask equipped with a stir bar was 
charged with 13C labeled ethynyltrimethylsilane 99 atom% (Aldrich, 0.4 mL, 2.83 mmols, 1.0 
equiv.) 2.14 and THF (5 mL). The flask was cooled in a -78 oC IPA/dry ice bath for 15 minutes 
and n-butyllithium (1.8 mL, 1.6 M in hexanes, 2.88 mmols, 1.02 equiv.) was added dropwise. 
The reaction was placed in a 0 oC ice bath and stirred for 25 minutes. The -78 oC IPA/dry ice 
bath was replaced and the flask was cooled at -78 oC for 15 minutes. To the flask, 
triethylgermanium chloride (0.47 mL, 2.84 mmols, 1.0 equiv.) was added dropwise. The reaction 
was allowed to warm to room temperature and stirred for 14 hours. To the flask was added 
saturated NH4Cl (2 mL) and the solution was poured into a separatory funnel containing brine 
(25 mL) and Et2O (25 mL). The organic layer was separated, dried over MgSO4, filtered and 
solvent removed in vacuo to give a yellow oil. The crude product was purified by silica gel 
chromatography (hexanes) to give the product 2.15 as a colorless oil (602 mg, 82% yield). 
 
1H-NMR (400 MHz, CDCl3) 
 δ 1.08 (t, J = 7.8 Hz, 9H), 0.84 (qd, J = 7.8, 2.1 Hz, 6H), 0.16 (d, J = 2.4, 9H)  
 
13C-NMR (100 MHz, CDCl3) 











Calculated for 12C913C2H25GeSi (M+H)+:   261.1 
Found:       261.1 
 
 
13C Bis-metallated olefin 2.16 A flame dried 7 mL vial equipped with a stir bar was charged in 
order with 13C labeled alkyne 2.15 (600 mg, 2.08 mmols, 1.0 equiv.), MeOH (3.9 mL) and 3M 
NaOH (0.777 mL, 2.33 mmols, 1.1 equiv.). The vial was stirred for 20 minutes at room 
temperature and then poured into a separatory funnel containing 1M HCl (2.4 mL), brine (20 
mL) and Et2O (20 mL). The aqueous layer was extracted with Et2O (3 x 20 mL) and the 
combined organics were washed with brine (1 x 50 mL). The organic layer was separated, dried 
with MgSO4, filtered and solvent removed in vacuo to give the product as a colorless oil. The 
crude product was used in the subsequent reaction without further purification. (Note: The water 
bath for the rotatory evaporator was maintained at 0 oC to prevent distillation of the volatile 
product.) A 20 mL vial equipped with a stir bar was charged with the crude 13C alkyne and 
AIBN (38 mg, 0.231 mmols, 0.1 equiv.) and purged with Ar for 10 minutes. To the vial was 
added HSnBu3 (0.81 mL, 3.00 mmols, 1.45 equiv.) and toluene (5 mL). The vial was sealed and 
heated with stirring to 100 oC for 22 hours. Solvent was removed in vacuo, CCl4 (5 mL) was 
added and the solution was stirred for 30 minutes. To the vial, saturated KF (2.5 mL) and H2O 
(2.5 mL) were added and the solution was stirred for 2 hours. The reaction was poured in brine 







with brine (1 x 50 mL), dried with MgSO4, filtered and solvent removed in vacuo. The crude 
product was purified by silica gel chromatography (petroleum ether) to give 2.16 as a colorless 
oil (639 mg, 64% yield). 
 
TLC (hexanes)  
 Rf = 0.79, visualized by short wave UV and stained with KMnO4  
 
1H-NMR (500 MHz, CDCl3) 
δ 6.80 (ddd, J = 145.5, 22.3, 3.1 Hz, 1H), 6.61 (ddd, J = 145.1, 22.3, 3.0 Hz, 1H), 1.52-
1.47 (m, 6H), 1.34-1.27 (m, 6H),1.01 (t, J = 7.9 Hz, 9H), 0.91-0.88 (m, 15 H), 0.77 (qd, J 
= 8.0, 1.5 Hz, 6H)  
 
13C-NMR (125 MHz, CDCl3)  
 δ 151.2 (d, J = 51.7 Hz), 148.9 (d, J = 51.7 Hz), 29.3, 27.4, 13.9, 9.6, 9.1, 4.3 
 
 
13C Trienyl germanium 2.18. A flame dried 40 mL vial equipped with a stir bar was charged 
with MIDA boronate 2.171  (203 mg, 0.582 mmols, 1.0 equiv.) and taken into the glovebox. To 
the vial was added CuTC (167 mg, 0.876 mmols, 1.5 equiv.) and Pd(PPh3)4 (36 mg, 0.031 
mmols, 0.05 equiv.). The vial was taken out of the glovebox and DMF (6 mL) and 2.16 (340 mg, 






















for 5 hours. The reaction was poured into brine (100 mL) and extracted with EtOAc (3 x 75 mL). 
The combined organics were washed with brine (2 x 50 mL), dried with MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by silica gel chromatography (100:0 to 
90:10 Et2O:MeCN) to give 2.18 as a yellow solid (143 mg, 51% yield). 
 
TLC (Et2O:MeCN 4:1)  
 Rf = 0.65, visualized by short wave UV and stained by KMnO4 
 
1H NMR (500 MHz, d6-acetone) 
δ 6.67 (dddd, J = 151, 18, 10, 3 Hz, 1H), 6.67 (ddd, J = 14.5, 11, 7 Hz, 1H), 6.43 (d, J = 
11 Hz, 1H), 6.29 (dd, J = 14.5, 10.5, 1H), 6.08 (ddd, J = 143, 18, 5 Hz, 1H), 4.23 (d, J = 
16.5 Hz, 2H), 4.06 (d, J = 17 Hz, 2H), 2.97 (s, 3H), 1.82 (s, 3H), 1.04 (t, J = 8 Hz, 9H), 
0.83 (qd, J = 8, 1.5 Hz, 6H) 
 
13C NMR (125 MHz, d6-acetone)  
δ 169.2, 145.7 (d, J = 61 Hz), 137.0 (d, J = 7.625 Hz), 136.6 (d, J = 53.75 Hz) 129.5 (d, J 
= 8.75 Hz), 133.0 (d, J = 61 Hz), 62.6, 47.1, 15.3, 9.2, 4.8 
 
HRMS (ESI+) 
Calculated for 12C1613C2H31BGeNO4 (M+H)+:  412.1625 




13C BB3 Trienyl iodide. A flame dried 7 mL vial equipped with a stir bar was charged with 2.18 
(64.4 mg, 0.16 mmols, 1.0 equiv.), placed under Ar and MeOH (3 mL) was added. The vial was 
cooled (15 min.) in an IPA/dry ice bath at -78 oC. In a second flame dried 7 mL vial charged with 
I2 (freshly sublimed, 123 mg, 0.485 mmols, 3.0 equiv.) was added MeOH (1.5 mL). The I2 
solution was cooled in an IPA/dry ice bath at -78 oC for 10 minutes and then was added dropwise 
in three separate portions to the vial containing 2.18 while in the -78 oC IPA/dry ice bath. The 
reaction was stirred for 3 hours 20 minutes at -78 oC under Ar. The solution was then quickly 
transferred to a 125 mL Erlenmeyer flask equipped with a stir bar containing 50 mL sat. NaHSO3 
and 25 mL EtOAc while vigorously stirring the solution. The vial was washed with EtOAc (2 x 
10 mL) to ensure quantitative transfer. The solution was transferred to a separatory funnel and 
the aqueous layer was removed. The organic layer was then washed with sat. NaHSO3 (3 x 50 
mL) and brine (2 x 50 mL), dried with MgSO4, filtered and solvent removed in vacuo. The 
remaining tan solid was triturated with 1:1 Et2O:hexanes (3 x 10 mL) to give an off-white solid 



























































13C tetraene 2.19. To a 7 mL vial equipped with a stir bar was added 13C BB1 (88.3 mg, 0.195 
mmols, 1.0 equiv.). The starting material was dissolved in THF (2.0 mL), stirred vigorously and 
1M NaOH (0.60 mL, 0.60 mmols, 3.0 equiv.) was added. The reaction was stirred for 25 minutes 
until no more MIDA boronate remained by TLC. The reaction was poured into phosphate buffer 
(25 mL, 0.5 M, pH 7.0) and extracted with Et2O (3 x 10 mL). The organics were combined, dried 
over MgSO4, filtered and solvent removed in vacuo to give a white solid (55 mg, 83% yield). 
The crude solid was used without further purification in the next reaction. 
To a flame-dried 7 mL vial was added BB21 (45.5 mg, 0.133 mmols, 1.0 equiv.) and the 
vial was taken into the glovebox. In the glovebox, a 7 mL vial was charged with Pd(OAc)2 (2.25 
mg, 0.010 mmols, 0.08 equiv.) and XPhos (10.5 mg, 0.022 mmols, 0.18 equiv.) and THF (0.4 
mL) was added. The vial was stirred in the glovebox at room temperature for 15 min. To the vial 
containing BB2 was added K3PO4 (76 mg, 0.357 mmols, 2.9 equiv.) followed by 13C BB1 boronic 
acid as a solution in THF:toluene (1:2, 2 x 0.9 mL). The catalyst solution was added to the 
reaction. The reaction vial was taken out of the glovebox, sealed and stirred at 45 oC for 24 
hours. The reaction was cooled to room temperature, diluted with EtOAc and filtered over celite. 
The solvent was removed in vacuo and purified by flash chromatography on florosil 
(Et2O:MeCN 100:0 to 80:20) to give 2.19 as a yellow solid (41.2 mg, 57% yield). 
 
TLC (4:1 Et2O:MeCN) 
 Rf = 0.61, stained by KMnO  
 
1H-NMR (500 MHz, d6-acetone) 
!94 
δ 7.52 (s, 1H), 7.19 (dd, J = 159.0, 15.7 Hz, 1H), 6.40 (dd, J = 15.6, 3.7 Hz, 1H), 5.93 (s, 
1H), 5.82 (s, 1H), 4.26 (d, J = 17.0 Hz, 2H), 4.09 (d, J = 16.9 Hz, 2H), 3.89 (m, 1H), 3.10 
(s, 3H), 2.27-2.22 (m, 4H), 1.72 (dd, J = 14.4, 8.3 Hz, 1H), 1.53 (ddd, J = 13.0, 3.4, 1.6 
Hz, 1H), 1.33-1.25 (m, 1H), 1.20 (s, 3H), 1.16 (s, 3H), 0.95 (s, 3H), 0.89 (s, 9H), 0.08 (s, 
3H), 0.07 (s, 3H)  
 
13C-NMR (125 MHz, d6-acetone) 
δ 169.2, 168.9, 147.2, 146.4, 138.8 (d, J = 6.5 Hz), 135.0, 126.6, 122.3 (d, J = 72.5), 
121.0, 70.8 (d, J = 55.6 Hz), 67.8, 65.6, 62.6, 47.7, 47.2, 42.2, 35.7, 35.7, 26.2, 25.4, 
20.2, 18.7, 18.6, -4.6, -4.6 
 
HRMS (ESI+) 
Calculated for 12C2913CH45BNO8Si (M)+: 587.3041   




13C heptaene 2.20. A 7 mL vial equipped with a stir bar was charged with tetraene MIDA 




















































NaHCO3 (54 mg, 0.643 mmols, 6.1 equiv.) and MeOH (1.1 mL) was added. The vial was sealed 
and stirred at 45 oC for 3 hours. The reaction was cooled to room temperature, diluted with 
EtOAc and filtered through celite. The solvent was then removed in vacuo, crude material 
transferred to a 7 mL vial and azeotroped with toluene (3 x 1 mL). To the vial was added a stir 
bar, CaCl2 (58 mg, 0.523 mmols, 5.0 equiv.), NaHCO3 (45 mg, 0.536 mmols, 5.1) and toluene 
(1.1 mL). The vial was stirred at room temperature for 3 hours. The solution was then diluted 
with EtOAc, filtered through celite and solvent removed in vacuo to give a yellow solid (59 mg). 
The product 2.25 was used in the subsequent coupling reaction without further purification. 
The two coupling partners 13C BB3  (50.1 mg, 0.133 mmols, 1.3 equiv.) and 2.25 (59 mg, 
0.105 mmols, 1.0 equiv.) each in flame dried 7 mL vials were taken into the glovebox. To the 
vial containing BB3 was added PdCl2(PPh3)2 (6.0 mg, 0.0086 mmols, 0.08 equiv.) and Ag2O (78 
mg, 0.337 mmols, 3.2 equiv.). BB3 was transferred into the reaction vial by dissolving in three 
sequential portions of DMSO (0.4 mL, 0.4 mL and 0.3 mL). The vial was sealed, taken out of the 
glovebox, heated to 45 oC and stirred as a sealed vessel for 13 hours. The reaction was cooled to 
room temperature, diluted with EtOAc (10 mL) and transferred to a separatory funnel containing 
brine (25 mL). The aqueous layer was extracted with EtOAc (3 x 25 mL). The organics were 
combined, washed with brine (2 x 25 mL), dried with MgSO4, filtered and solvent removed in 
vacuo. The crude red solid was purified by reverse phase chromatography on C18 silica gel 
(40:60 to 5:95 H2O:MeCN) to give 2.20 as a red solid (28.1 mg, 39% yield). 
 
TLC (Et2O:MeCN 4:1) 
 Rf = 0.42, visualized by visible light (orange) 
 
!96 
1H-NMR (500 MHz, d6-acetone) 
δ 7.50 (s, 1H), 7.18 (dd, J = 158.5, 15.7 Hz, 1H), 6.86 – 6.76 (m, 2H), 6.66 – 6.56 (m, 
2H), 6.52 – 6.46 (m, 2H), 6.41 (dd, J = 16, 3.5 Hz, 1H), 6.00 (s, 1H), 4.24 (d, J = 17.0 
Hz, 2H), 4.07 (d, J = 16.9 Hz, 2H), 3.89 (m, 1H), 2.98 (s, 3H) 2.27-2.23 (m, 1H) 2.21 
(s,3H), 1.84 (s, 3H), 1.71 (dd, J = 14.4, 8.3 Hz, 1H), 1.53 (ddd, J = 13.0, 3.2, 1.6 Hz, 1H), 
1.31 (dd, J = 13.0, 10.0, 1H), 1.20 (s, 3H), 1.17 (s, 3H), 0.95 (s, 3H), 0.89 (s, 9H), 0.08 (s, 
3), 0.07 (s, 3H) 
  
13C-NMR (125 MHz, d6-acetone) 
 δ 169.2, 169.2, 148.0, 138.3 (d, J = 68.5 Hz), 138.2 (d, J = 68.5 Hz), 137.7, 137.0 (d, J = 
68.625), 134.9 134.53 (d, J = 2.875 Hz), 134.45, 130.3 (d, J = 68.5 Hz), 130.1, (d, J = 
68.5 Hz), 125.4, 122.8, 119.6 (d, J = 7.5 Hz), 70.8 (d, J = 55.75 Hz), 67.8, 65.6, 62.7, 
47.7, 47.2, 42.0, 35.8, 27.6, 26.2, 25.5, 20.2, 18.6, 15.5, 15.4, -4.5, -4.6 
 
HRMS (ESI+) 
Calculated for 12C3413C3H53BNO8Si (M+H)+: 681.3734   




13C protected peridinin 2.26. Catalyst Solution: In the glovebox, a 7 mL vial equipped with a 
stir bar was charged with Pd(OAc)2 (2.5 mg, 0.011 mmols), Xphos (10.5 mg, 0.021 mmols) and 
THF (2 mL). Catalyst solution was stirred for 20 minutes at room temperature prior to use.  
In the glovebox, a 7 mL vial equipped with a stir bar in the glovebox was charged with 
13C heptaene 2.19 (15 mg, 0.0220 mmols, 1.0 equiv.) and NaOH (oven dried, 7 mg, 0.175 
mmols, 8.0 equiv.). To the vial was added a THF (0.55 mL) solution of 13C BB4 (12.1 mg, 
0.0286 mmols, 1.3 equiv.) and 0.2 mL of the catalyst solution (see above). The vial was capped 
with a septum, removed from the glovebox, placed under Ar and H2O (purged with Ar for 30 
min., 0.15 mL) was added. The reaction was stirred at room temperature for 1.5 hours under Ar. 
The reaction was poured into phosphate buffer (10 mL, 0.5 M, pH 7.0) and extracted with Et2O 
(3 x 10 mL). The combined organics were washed with brine (2 x 10 mL), dried with MgSO4, 
filtered and solvent removed in vacuo to give a red solid. The crude solid was purified by reverse 
phase chromatography on C18 silica gel (95:5 to 50:50 MeCN:EtOAc) to give 2.26 as a red solid 
(11.3 mg, 63% yield). 
 
TLC (hexanes:EtOAc) 






































1H-NMR (500 MHz, d6-acetone)  
δ 7.51 (s, 1H), 7.17 (dd, J = 158.4, 15.8 Hz, 1H), 6.81-6.73 (m, 2H), 6.61-6.59 (m, 1H), 
6.53-6.47 (m, 2H), 6.40 (dd, J = 15.5, 3.7 Hz, 1H), 6.22 (d, J = 11.6 Hz, 1H), 6.11 (d, J = 
2.6 Hz, 1H), 6.00 (s, 1H), 5.32 (m, 1H), 3.90 (m, 1H), 2.27-2.23 (m, 1H), 2.21 (s, 3H), 
2.17 (dt, J = 4.3, 2.1 Hz, 1H),1.98 (s, 3H), 1.93-1.91 (m, 1H), 1.85 (s, 3H), 1.72 (dd, J = 
14.6, 8.3 Hz, 1H), 1.55-1.52 (m, 1H), 1.49-1.31 (m, 3H), 1.41 (s, 3H), 1.35 (s, 3H), 1.20 
(s, 3H), 1.17 (s, 3H), 1.07 (s, 3H), 0.95 (s, 3H), 0.89 (s, 9H), 0.13 (s, 9H), 0.08 (s, 3H), 
0.07 (s, 3H). 
 
HRMS (ESI+) 
Calculated for 12C4413C4H73O7Si2 (M+H)+:  821.5029   




13C peridinin. HF!pyridine Stock Solution: To an oven dried 2.5 mL Teflon vial equipped with a 
































HF!pyridine (70% HF in pyridine, new bottle, 0.25 mL) was added. Note: Wet HF!pyridine 
solution leads to significant product decomposition. 
To an oven dried 2.5 mL Teflon vial equipped with a stir bar under Ar was added 13C 
protected peridinin 2.26 (5.8 mg, 0.00705 mmols, 1.0 equiv.) by dissolving in Et2O and blowing 
off the solvent under a gentle stream of Ar. The vial was then placed back under Ar and THF 
(0.35 mL) was added. The vial was then cooled in a 0 oC ice bath and HF!pyridine stock solution 
(0.15 mL) was added dropwise. The ice bath was removed and the reaction was stirred at room 
temperature for 4 hours. The vial was diluted with Et2O (1 mL) and transferred to a separatory 
funnel containing Et2O (10 mL) and sat. NaHCO3 (20 mL). The aqueous layer was extracted 
with Et2O (4 x 20 mL). The combined organics were dried with MgSO4, filtered and solvent 
removed in vacuo to give a red solid. The crude product was purified by reverse phase semi-prep 




Column: Sunfire Prep C18, 5 mm, 10 x 250 mm 
Flow Rate: 5 mL/min 
Solvent: 25:75 H2O:MeCN 
Elution Time: 16.8 min. 
 
TLC (hexanes:acetone 7:3) 
 Rf = 0.27, visualized by visible light (orange) 
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1H-NMR (500 MHz, CDCl3) 
δ 7.17 (dd, J = 160.2,15.6 Hz, 1H), 7.02 (s, 1H), 6.78-6.58 (m, 2H), 6.46-6.36 (m, 3H), 
6.37 (dd, J = 15.4, 3.8 Hz, 1H), 6.11 (d, J = 11.6 Hz, 1H), 6.05 (d, J = 2.6 Hz, 1H). 5.73 
(s, 1H), 5.38 (m, 1H), 3.90 (m, 1H), 2.40 (ddd, J = 14.4, 5.0, 1.6 Hz, 1H), 2.28 (ddd, J = 
12.4, 4.0, 1.9 Hz, 1H), 2.23 (s, 3H), 2.04 (s, 3H), 1.99 (ddd, J = 12.8, 4.4, 2.4 Hz, 1H), 
1.80 (s, 3H), 1.67-1.56 (m, 2H), 1.53-1.48 (m, 1H), 1.43-1.35 (m, 2H), 1.38 (s, 3H), 1.35 
(s, 3H), 1.26 (m, 1H), 1.203 (s, 3H), 1.199 (s, 3H), 1.07 (s, 3H), 0.97 (s, 3H)  
 
13C NMR (125 MHz, CDCl3, 13C enriched signals only)   
δ 202.88, 137.44 (d, J = 69.2 Hz), 133.85, 129.14 (d, J = 69.3 Hz) 
 
HRMS (ESI+) 
Calculated for 12C3513C4H51O7 (M+H)+:  635.3769   
Found:       635.3743  
 
IV. SYNTHESIS OF RENIERAPURPURIN 
 
 
Aryl diene 2.21. In a glovebox, to a flame-dried 20 mL vial equipped with a stirbar and charged 
with aryl iodide BB5 (150 mg, 0.610 mmol, 1.2 equiv.) and bisborylated diene BB6 (177 mg, 






























ground anhydrous K3PO4 (647 mg, 3.05 mmol, 6.0 equiv.) and DMSO (4 mL). The vial was 
sealed with a PTFE-lined cap and removed from the glove box. The vial was stirred at 45 °C in 
an aluminum heat block for 24 hr and was then cooled to 23 °C. The reaction was transferred to a 
separatory funnel, diluting with 10 mL EtOAc. The organic layer was washed with brine:H2O 
(1:1, 2 x 20 mL) to remove DMSO, dried over MgSO4, filtered, and concentrated in vacuo to 
afford an orange oil. The crude material was adsorbed onto Celite from an acetone solution and 
purified by SiO2 flash chromatography (petroleum hexanes:EtOAc 1:1 → EtOAc) to afford aryl 
diene 2.21 as a light orange solid (121 mg, 70% yield). 
 
TLC (EtOAc) 
 Rf = 0.57, visualized by UV (λ = 254 nm) and stained by KMnO4 
 
1H NMR (500 MHz, d6-acetone)  
δ  7.23 (d, J = 7.9 Hz, 1H), 6.95 (d, J = 8.1, 1H), 6.90 (d, J = 15.9, 1H), 6.69 (d, J = 15.9, 
1H), 5.51 (s, 1H), 4.22 (d, J = 17.0, 2H), 4.06 (d, J = 16.9, 2H), 3.06 (s, 3H), 2.27 (s, 3H), 
2.24 (s, 3H), 2.17 (s, 3H), 2.07 (s, 3H).   
 
HRMS (ES+) 
Calculated for C19H25BNO4 (M+H)+:  342.1877 




























Aryl pinacol boronic ester 2.23.   To a 7 mL vial equipped with a stirbar was added aryl diene 
2.21 (59.6 mg, 0.175 mmol, 1.0 equiv.), pinacol (41.3 mg, 0.349 mmol, 2.0 equiv.), and solid 
NaHCO3 (73.4 mg, 0.874 mmol, 5.0 equiv.). The vial was sealed with a PTFE-lined cap, flushed 
with nitrogen, and MeOH (0.9 mL) was added via syringe to afford a cloudy light orange 
solution. The vial was stirred at 45 °C in an aluminum heat block for 3 hr and was then cooled to 
23 °C. The reaction mixture was filtered through a pad of Celite, rinsing with Et2O, and the 
solution concentrated in vacuo in a 50 mL round bottom flask. To remove residual pinacol, 
finely ground CaCl2 (271 mg, 2.45 mmol, 14 equiv.), solid NaHCO3 (73.4 mg, 0.874 mmol, 5.0 
equiv.), and toluene (5.8 mL) were added to the flask containing the crude material. The 
resulting cloudy suspension was stirred at 23 for 1 hr and filtered through a pad of Celite, rinsing 
with Et2O, and concentrated in vacuo to afford an orange oil. The crude material was adsorbed 
onto Celite from an acetone solution and purified by SiO2 flash chromatography (hexanes:EtOAc 
9:1) to afford aryl pinacol boronic ester 2.23 as a light orange solid (46.4 mg, 85% yield). 
 
TLC (hexanes:EtOAc 9:1) 
 Rf = 0.25, visualized by UV (λ = 254 nm) and stained by KMnO4 
 
1H NMR (500 MHz, d6-acetone)  
δ  7.26 (d, J = 8.0 Hz, 1H), 7.05 (d, J = 15.9, 1H), 6.97 (d, J = 7.8, 1H), 6.71 (d, J = 15.8, 

































Tetraenyl MIDA boronate 2.24.    In a glovebox, to a flame-dried 20 mL vial equipped with a 
stirbar and charged with aryl pinacol boronic ester 2.23 (322 mg, 1.03 mmol, 1.2 equiv.) and 
dienyl iodide BB8 (300 mg, 0.860 mmol, 1.0 equiv.) was added PdCl2(dppf)!DCM (35.1 mg, 
0.0430 mmol, 5 mol%), finely ground anhydrous K3PO4 (1.10 g, 5.16 mmol, 6.0 equiv.) and 
DMSO (5.8 mL). The vial was sealed with a PTFE-lined cap and removed from the glove box. 
The vial was stirred at 45 °C in an aluminum heat block for 24 hr and was then cooled to 23 °C. 
The reaction was transferred to a separatory funnel, diluting with 15 mL EtOAc. The organic 
layer was washed with brine:H2O (1:1, 2 x 30 mL) to remove DMSO. The aqueous phase was 
extracted with EtOAc (1 x 15 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo to afford an orange oil. The crude material was adsorbed onto 
Celite from an acetone solution and purified by SiO2 flash chromatography (hexanes:EtOAc 1:1 
to EtOAc) to afford tetraenyl MIDA boronate 2.24 as an orange solid (137 mg, 39% yield). 
 
TLC (EtOAc) 
 Rf = 0.26, visualized by UV (λ = 365 nm) 
 
1H NMR (500 MHz, d6-acetone)  
δ  7.27 (d, J = 8.0 Hz, 1H), 6.96 (d, J = 7.9 Hz, 1H), 6.93 (d, J = 15.7 Hz, 1H), 6.75 (d, J 
= 16.1 Hz, 1H), 6.42 (d, J = 15.3 Hz, 1H), 6.32 (d, J = 11.3 Hz, 1H), 5.46 (s, 1H), 4.21 
(d, J = 16.9 Hz, 2H), 4.04 (d, J =17.0 Hz, 2H), 3.03 (s, 3H), 2.28 (s, 3H), 2.24(s, 3H), 




Calculated for C24H31BNO4 (M+H)+:  408.2346 




Renierapurpurin. Preparation of stock solutions. In a glovebox, to a 7 mL vial was added 
XPhos and THF (4.3 mg/mL) to afford a clear solution. To a second 7 mL vial was added 
Pd(OAc)2 and THF (1.1 mg/mL) to afford a pale yellow-orange solution. To a separate 7 mL vial 
was added trans-1-iodo-2-bromoethylene BB7 and THF (21.0 mg/mL). 
The freshly prepared stock solutions were used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with stirbar and charged with tetraenyl MIDA boronate 2.24 (19.7 mg, 
0.0484 mmol, 2.2 equiv.) was added finely ground solid NaOH (12 mg, 0.307 mmol, 14.0 
equiv.). The stock solution of BB7 in THF (0.244 mL, containing 5.1 mg, 0.022 mmol, 1.0 
equiv.) was added to the reaction vial followed by the XPhos stock solution (0.244 mL, 
containing 1.05 mg, 0.0022 mmol, 10 mol%) and the Pd(OAc)2 stock solution (0.244 mL, 
containing 0.268 mg, 0.0011 mmol, 5 mol%). The vial was sealed with a PTFE-lined septum 
cap, removed from the glovebox, and stirred at 23 °C for 5 min. Degassed DI H2O (0.147 mL, 
0.15 M) was added dropwise. The solution was stirred in a subdued light environment at 23 °C 
























to a separatory funnel with Et2O (10 mL). The layers were separated and the aqueous layer was 
extracted with Et2O (2 x 10 mL), dried over MgSO4, filtered, and concentrated in vacuo to afford 
a dark red solid. The resulting residue was adsorbed onto Celite from an acetone solution and 
purified by SiO2 chromatography (hexanes) to afford renierapurpurin (2.3 mg, 20% yield 
unoptimized).  
 
TLC (hexanes:EtOAc 10:1) 
 Rf = 0.89, visualized by visible light (orange) 
 
1H NMR (500 MHz, CD2Cl2) All peaks not assigned  
δ  7.25 (d, J = 8.0 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.89, (d, J = 15.5, 1H), 2.30 (s, 3H), 
2.28 (s, 3H), 2.21 (s, 3H), 2.07 (s, 3H).    
 
HRMS (ES+) 
Calculated for C40H48 (M)+: 528.3756 
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 Lipid peroxidation is widely cited as an important and addressable contributor to the 
pathogenesis of asthma, yet this hypothesis has remained unverified. The current mechanistic 
model proposes that ROS released by inflammatory leukocytes initiate the free-radical 
propagation of lipid peroxidation, leading to the formation of toxic electrophilic breakdown 
products and pro-inflammatory signaling molecules. This process may thereby exacerbate the 
allergic inflammation characteristic of the disease. With the goal of determining whether lipid 
peroxidation functions in a causative or simply correlative role in the pathogenesis of asthma, we 
sought to apply peridinin as a potent small molecule antilipoperoxidant probe in a mouse model 
of acute asthma. Applying both ovalbumin and house dust mite models, we found that antigen 
challenge consistently resulted in a robust asthmatic response, yet highly variable lipid 
peroxidation phenotype. This divergence suggests that lipid peroxidation is not a critical 
contributor to the pathogenesis of acute asthma.     
 This work was performed in collaboration with Adam G. Hill. Design of the experiments, 
peridinin synthesis, and analysis of lipid peroxidation was performed with Adam G. Hill. The 
animal models were conducted by Dr. Xiaozhu Huang, Xin Ren, and Kieu My Huynh at the 
Sandler Asthma Basic Research Center at the University of California, San Francisco.  
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3-1 LIPID PEROXIDATION IS PROPOSED TO CONTRIBUTE TO THE 
PATHOGENESIS OF ASTHMA 
Asthma is a chronic inflammatory disease which causes both acute airway constriction 
and long-term airway remodeling.1 Disease pathogenesis is initiated with the recognition of an 
environmental allergen (i.e. house dust mites, Aspergillus, viruses, air pollution, or certain drugs 
and chemicals)2 by T lymphocytes, primarily type 2 helper (Th2) cells. In response, these cells 
upregulate the production of immunoglobulin E (IgE),3 recruitment of inflammatory cells 
(eosinophils, neutrophils and macrophages),1 and proinflammatory cytokines (primarily the 
interleukins IL-3, IL-4, IL-5, IL-9, IL-13, IL-33,4, 5 nuclear factor-κβ,6 C-reactive protein,7 and 
tumor necrosis factor-α8). This inflammatory response leads to further airway damage via loss of 
epithelial tight junctions,9 mucus production,9 and airway remodeling,10 (i.e. smooth muscle 
hyperplasia and hypertrophy,10 vascularization,11 fibrosis,12 and collagen deposition13). 
Degradation of the epithelial barrier in conjunction with the development of highly reactive 
airway smooth muscle causes increased airway hyperresponsiveness and the characteristic 
asthma pathophysiology. 
Lipid peroxidation is hypothesized to be an important driver of both the exaggerated 
inflammatory response and airway remodeling that is characteristic of asthma (Figure 3-1).1, 2, 10, 
14-17 In this model, ROS released by inflammatory leukocytes, including activated eosinophils, 
neutrophils, monocytes, and macrophages15 in response to antigens, initiate the non-enzymatic 
peroxidation of PUFAs present in the membranes of bronchial epithelial and smooth muscle 
cells.18 This is followed by extensive propagation of lipid peroxidation resulting in electrophilic 
breakdown products such as malondialdehyde  (MDA) and 4-hydroxy-2-nonenal (HNE)18 which 
are toxic to cells, and mimics of pro-inflammatory signaling molecules such as 8-iso-
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prostaglandin F2α (8-iso-PGF2α),19 which further promote inflammation. Thus, a normally 
innocuous irritant initiates a self-propagating pathway of lipid peroxidation that helps drive the 
pathophysiology of asthma.     
 
 
At present, this model is supported primarily by correlative evidence. For example, 
correlations have been found between asthma severity and lipid peroxidation products in the 
bronchoaveolar lavage fluid (BALF) and breath condensate of asthmatic patients, including 
MDA,20, 21 HNE,22 and 8-iso-PGF2α.23-25
 Genetic studies have also revealed correlations between 
asthma and deficiencies of endogenous antioxidant proteins, including superoxide dismutase26 
and glutathione transferase.27, 28 Similarly, knockout mice deficient in either glutathione 
peroxidase29 or transferase30 show an exaggerated asthmatic response. It has also been 
demonstrated that lipid breakdown products induce the loss of bronchial epithelial tight junctions 
and induce mucus production in vitro,9, 31, 32 two key characteristics of an asthma phenotype. 
While these studies suggest a potential role for lipid peroxidation in the pathogenesis of asthma, 
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Figure 3-1. Lipid peroxidation is proposed to contribute to the pathogenesis of asthma through the 
formation of toxic or proinflammatory products, which promote an exaggerated inflammatory 
response. Small molecule antilipoperoxidants may have the capacity to attenuate the lipid peroxidation 
phenotype.     
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This gap in knowledge is due in part to the lack of a suitable small molecule 
antilipoperoxidant to probe these questions. Previous studies aimed at directly chemically 
inhibiting lipid peroxidation in murine asthma models have yielded contradictory results.33 For 
example, it remains unclear whether vitamin E or its derivatives are able to significantly 
diminish lipid peroxidation in vivo34 and whether they ameliorate35 or exacerbate36, 37 the 
inflammation seen in a murine model of asthma. Additionally, high oral doses of N-
acetylcysteine, a glutathione precursor, have been shown to decrease the asthma phenotype in 
murine asthma models.38, 39 However, clinical trials of N-acetylcysteine in chronic obstructive 
pulmonary disease patients, as no trials have been run in asthma patients, have thus far 
demonstrated no significant benefit at daily doses of 600 mg.40 The demonstrated capacity of 
peridinin to potently inhibit membrane lipid peroxidation in endothelial cells and thereby clarify 
the role of this process in endothelial-monocyte binding and atherogenesis suggested its utility 
towards understanding the contribution of lipid peroxidation in the pathogenesis of asthma.  
 
3-2 PROBING THE ROLE OF LIPID PEROXIDATION IN MOUSE MODELS OF 
ACUTE ASTHMA 
 We therefore sought to utilize peridinin to probe the role of lipid peroxidation in a mouse 
model of acute asthma. Although the pathophysiology of asthma in humans is complex and 
cannot be fully mimicked in any animal system, mice have become the most commonly utilized 
animal for modeling the asthmatic phenotype.41 Mice can be sensitized to both unnatural 
antigens, such as the protein ovalbumin (OVA), and environmentally occurring human allergens 
including house dust mite (HDM). Following sensitization, the immune system develops a 
reaction to the antigen, resulting in a robust allergic response upon subsequent antigen 
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challenge.42 Such mouse models result in a Th2-dominant immune response, consistent with that 
observed in human allergic asthma. A strong inflammatory reaction in the airway characterized 
by increased concentrations of antigen-specific IgE, inflammatory leukocytes, Th2 cytokines 
(including IL-4, IL-5, and IL-13), and airway hyperresponsiveness (AHR) is observed.  
Enhanced levels of lipid peroxidation have been observed in both the mouse OVA43 and 
HDM44 acute models of asthma, suggesting that peridinin could be utilized in either model to 
probe the role of lipid peroxidation in disease pathogenesis. We sought to initially begin our 
studies in the well-established acute OVA model to characterize both the lipid peroxidation and 
asthmatic phenotypes, and the corresponding impact of peridinin treatment. The purity and 
uniformity of the ovalbumin antigen results in a highly reproducible and robust asthmatic 
phenotype.  
To obtain the necessary quantities of peridinin to deliver in the mouse model, we scaled 
up the reported building block based synthesis.45 We sought to deliver peridinin via intranasal 
instillation, which allows for direct delivery of the compound to the respiratory tract.46 The 
hydrophobicity of peridinin renders it water insoluble, however, representing a significant 
challenge for compound administration.  The SSNMR results indicating that peridinin is 
completely inserted in the hydrophobic core of POPC bilayers suggested to opportunity to 
deliver peridinin as a liposomal formulation (Section 2-8).47  
Peridinin had never to the best of our knowledge been previously delivered intransally to 
mice, therefore we were required to determine the range of tolerated doses. In collaboration with 
Dr. Xiaozhu Huang, we found that peridinin is well-tolerated in wild-type BALB/c mice up to 5 
mg/kg for four consecutive days of intranasal administration as a formulation in POPC 
liposomes (MLVs) (Figure 3-2). Specifically, these concentrations resulted in no significant 
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toxicity as determined by quantification of body weight change and lung inflammation (Figure 3-
2b-d). Quantification of peridinin in the lung tissue and blood also demonstrated that peridinin is 
delivered to this tissue yet is not systemically distributed (Figure 3-2e-f). The highest dose tested, 
25 mg/kg, resulted in significant toxicity and accumulation in the blood.   
 
 
We were thus enabled to apply peridinin in an acute OVA mouse model of asthma 
(Figure 3-3a).48 Mice (BALB/c) were sensitized to OVA via intraperitoneal injection over 3 
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Figure 3-2. (a) Experimental design for evaluation of peridinin tolerance. (b) Intranasal delivery of 
peridinin POPC liposomes is well tolerated in wild-type mice up to 5 mg/kg as evidenced by no 
change in body weight and (c,d) no increase in lung tissue inflammation as observed by H&E 
staining. (e) Quantification of peridinin by HPLC in the left lung lobe shows dose-dependent 
accumulation. (f) No peridinin was observed in the blood at doses up to 5 mg/kg. Error bars 
represent SEM, n=4-5, **p < 0.01, ***p < 0.001, NS = p > 0.05     
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administered once per day beginning one day before and ending one day after the OVA 
challenge phase.  
 
 
Ovalbumin challenge caused a robust asthmatic phenotype relative to the saline control, 
but had minimal effect on lipid peroxidation in this experiment (Figure 3-3b-g) Specifically, 
airway hyperresponsiveness, OVA-specific IgE titers, leukocyte counts, lung inflammation, and 
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Figure 3-3. (a) Experimental design for delivery of peridinin in an acute OVA mouse asthma model. 
(b) Airway lipid peroxidation as determined by quantification of 8-iso-PGF2α in the BALF. Ovalbumin 
challenge does not significantly enhance lipid peroxidation. Ovalbumin challenge results in a robust 
asthmatic phenotype as indicated by enhancement of (c) AHR, (d) IgE, (e) macrophages (Macro.), 
eosinophils (Eos) lymphocytes (LC) and polymorphonuclear cells (PMN) in the BALF, (f) tissue 
inflammation, and (g) mucus production. Peridinin has no significant effect on lipid peroxidation or 
asthmatic phenotype. Error bars represent SEM, n=4-8, **p < 0.01, ***p < 0.001, NS = p > 0.05     
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strong asthmatic response. Alternatively, lipid peroxidation as determined by quantification of 8-
iso-PGF2α in the BALF via competitive ELISA demonstrated promising trends, yet no significant 
increase was observed upon OVA challenge (Figure 3-3b).  Peridinin demonstrated no effect on 
AHR nor any effect on airway inflammation. 
 
 
The failure of the ovalbumin challenge to induce lipid peroxidation in this experiment is 
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Figure 3-4. (a) Experimental design for OVA model and analysis. Acute asthmatic phenotype is 
observed as indicated by an increase in (b) airway hyperresponsiveness, (c) leukocytes in BALF, and 
(d) IgE in BALF. OVA-induced enhancement in lipid peroxidation was not observed in this 
experiment, as indicated by no increase in (e) 8-iso-PGF2α in the BALF (f) MDA in the BALF, (g) 8-
iso-PGF2α in the lung tissue, and (h) MDA in the lung tissue. Error bars represent SEM, n=10, *p < 
0.05, ***p < 0.001, NS = p > 0.05     
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of peridinin treatment to simply determine whether the protocol used is competent to induce this 
phenotype. In this second OVA model experiment, we included 10 mice per treatment group and 
quantified two markers of lipid oxidation (8-iso-PGF2α and MDA) in both the BALF and airway 
tissue (Figure 3-4a). The OVA sensitized and challenged mice exhibited the same exaggerated 
AHR phenotype and airway inflammation as observed in the first model (Figure 3-4b-d). In this 
experiment with higher statistical power and multiple lipid oxidation markers, no difference was 
again observed in lipid peroxidation between the OVA and saline-treated groups (Figure 3-4 e-
h). We thus concluded that lipid peroxidation is not a key driver of the asthmatic phenotype 
observed in the OVA mouse model of acute asthma utilized here.  
The absence of enhanced lipid peroxidation in this model is in direct contrast to the 
phenotype observed in asthmatic patients, suggesting that the OVA model may not reproducibly 
recapitulate this aspect of the human disease. We thus turned to the more clinically relevant 
HDM model of acute asthma to determine whether there is a measurable correlation between 
asthmatic phenotype and airway lipid peroxidation in this system. HDM is a more complex and 
heterogeneous allergen containing environmentally relevant protein and non-protein 
immunogenic components to which 50-85% of asthmatics are allergic.49 
We first determined whether lipid oxidation is induced concomitantly with the asthmatic 
phenotype by HDM challenge (Figure 3-5a). In this system, there is no strict distinction between 
the sensitization and challenges phases. Consistent with the capacity of this model to induce an 
asthmatic response, the HDM challenged group demonstrated increased AHR and airway 
inflammation as quantified by airway leukocyte counts and IgE titers (Figure 3-5b-d). The same 
four indicators of lipid oxidation were assessed and we found that in all cases, the HDM-exposed 
mice demonstrated significantly higher levels of oxidized lipids (Figure 3-5e-h). In the BALF, 
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dust mite challenge resulted in an approximate 2.5 fold increase in both 8-iso-PGF2α and MDA 
levels, while in the airway tissue, an approximate 1.5 fold increase in both markers was 
observed. These results indicate that significant asthma-associated lipid oxidation occurs in this 
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Figure 3-5. (a) Experimental design for HDM model and analysis. Acute asthmatic phenotype was 
observed as indicated by an increase in (b) airway hyperresponsiveness, (c) leukocytes in BALF, and 
(d) IgE in BALF. HDM-induced enhancement in lipid peroxidation was observed in this experiment, 
as indicated by a significant increase in (e) 8-iso-PGF2α in the BALF (f) MDA in the BALF, (g) 8-iso-
PGF2α in the lung tissue, and (h) MDA in the lung tissue. Error bars represent SEM, n=8-10, **p < 
0.01, ***p < 0.001     
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We therefore performed a final experiment in which we applied peridinin in the HDM 
model. We first aimed to determine whether peridinin treatment is able to significantly attenuate 
lipid peroxidation in the BALF and lung tissue, and if so, whether this effect is able to ameliorate 
the asthmatic phenotype. We specifically used a treatment protocol in which either vehicle, 1, or 
5 mg/kg peridinin was administered on days 14-16 and 21-23. Peridinin dosing on days 14 and 
21 was performed 6 hours before HDM challenge (Figure 3-6a). As observed in all previous 
experiments, a robust asthmatic phenotype was induced (Figure 3-6b-d). Analysis of the lipid 
peroxidation markers 8-iso-PGF2α and MDA, however, revealed inconsistent trends with respect 
to the capacity of the house dust mite challenge to induce this effect (Figure 3-6e-h). Only MDA 
in the BALF and 8-iso-PGF2α in the lung tissue was significantly increased in the vehicle-treated 
and challenged group relative to the corresponding unchallenged cohort. The data also indicated 
that peridinin treatment was generally unable to significantly attenuate either the lipid 
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3-3 SUMMARY AND CONCLUSIONS   
 Despite strong correlative connections between lipid peroxidation and an asthmatic 
phenotype in human patients, animal models, and in vitro studies, it has remained unclear 
whether this relationship is causative and therefore addressable. We sought to utilize peridinin as 
a potent inhibitor of non-enzymatic lipid peroxidation to understand whether attenuating this 
process would result in a similar attenuation of the asthmatic response in mouse models of acute 
saline HDM 
veh 5 mg/kg veh 1 mg/kg 5 mg/kg 
 












p = 0.042 
saline HDM 
























8-iso PGF2α in Lung Tissue 



















MDA in Lung Tissue 
saline HDM 
veh 5 mg/kg veh 1 mg/kg 5 mg/kg 
 






















8-iso PGF2α in BALF 
saline HDM 





Figure 3-6. (a) Experimental design for delivery of peridinin in the HDM model. An acute asthmatic 
phenotype was observed as indicated by an increase in (b) airway hyperresponsiveness, (c) leukocytes 
in BALF, and (d) IgE in BALF. The effects of HDM challenge on the lipid peroxidation phenotype 
were variable. No significant increase in (e) 8-iso-PGF2α in the BALF or (h) MDA in the lung tissue 
was observed, while significant increases in (f) MDA in the BALF and (g) 8-iso-PGF2α in the lung 
tissue were measured. Veh = vehicle. Error bars represent SEM, n=10, NS = p > 0.05      
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asthma. Evidence in the literature suggested a link between ovalbumin and house dust mite 
challenge and airway lipid peroxidation, however we found this correlation to be highly 
irreproducible. Although a robust asthmatic phenotype indicated by enhanced airway 
hyperresponsiveness and inflammation was consistently observed across four independent 
experiments, the corresponding lipid peroxidation phenotype was variable. Collectively, these 
results provide evidence that airway lipid peroxidation is not a necessary and critical driver of 
the acute asthmatic response. This suggests that further study or targeting of this oxidative 
process should focus on other pathways, such as the pathogenesis of chronic asthma.  
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General Methods.  
Materials. Commercially available materials were purchased from Sigma-Aldrich or Avanti 
Polar Lipids and were used without further purification unless stated otherwise.  Peridinin was 
synthesized as reported by Woerly and coworkers.1 Unless stated otherwise, all of the solvents 
were dispensed from a solvent purification system that passes solvents through packed columns 
according to the method described by Pangborn and coworkers (THF, Et2O, CH3CN, CH2Cl2: 
dry neutral alumina; hexanes, toluene: dry neutral alumina and Q5 reactant; DMSO, DMF, 
CH3OH: activated molecular sieves).2 Water was dispensed from a MilliQ water purification 
system (Millipore Corporation) unless stated otherwise.  
 
HPLC Analysis. All analytical HPLC analysis was performed using an Agilent 1200 series 
instrument equipped with a variable wavelength detector and analytical Agilent Eclipse XDB-
C18, 5 µm, 4.6 x 150 mm column. All HPLC solvents were filtered through 0.2-µm Millipore 
filters before use. Standard curves were utilized for quantitative determination of carotenoid and 
MDA content.   
 
Mice. All mice were female 6-8 week old wild-type BALB/c purchased from Jackson 
Laboratories. All mouse experiments were approved by the Institutional Animal Care and Use 
Committee of UCSF. 
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Samples for lipid peroxidation analysis. The supernatant from the bronchoalveolar lavage fluid 
(BALF) and the left lung lobe from each animal was frozen and shipped from UCSF to the 
Burke lab at UIUC overnight on dry ice. Samples were stored at -80 °C.  
 
I. ASSAY PROCEDURES 
Preparation of MLVs for mouse studies. Peridinin was dissolved in THF and the concentration 
was determined by analytical HPLC (average of three runs). Carotenoid solutions were diluted to 
between 2 and 7 mM in THF. To a 7 mL vial for each required dose was added the appropriate 
amount of carotenoid THF solution and solvent removed in vacuo. To each vial was added 
POPC (1.5 mg/dose/animal). Solvent was removed in vacuo and samples placed under high 
vacuum for ~24 hours. To each vial was added sterile saline (30 µL/dose/animal). The samples 
were sonicated and vortexed to form MLVs. The MLVs were subjected to five freeze/thaw 
cycles by submerging in liquid N2 and warm water. The samples were then frozen in liquid N2 
and water removed by lyophilization. The samples were stored as a dry powder at -20 oC under 
Ar and shipped overnight to UCSF on dry ice. 
 
Intranasal Administration of Peridinin. Liposome powders were rehydrated with water (30 
µL/dose/animal) and briefly vortexed to form a homogenous liposomal suspension. Each mouse 
was lightly anesthetized by isoflurane inhalation, held on its back and a single drop (30 µL) was 
placed on its nose. The sample was readily inhaled within the mouse airway. 
 
Peridinin Toxicity Studies. The toxicity study was performed in the laboratory of Xiaozhu 
Huang at the UCSF Sandler Asthma Basic Research Center. Mice were dosed by intranasal 
! 125 
administration with increasing concentrations of peridinin (0, 0.2, 1, 5 and 25 mg/kg) once per 
day for four consecutive days. On day five, the mice were weighed and sacrificed. Lung 
inflammation was measured by H&E staining (see Asthmatic Phenotype). 
 
Quantification of Peridinin in Mouse Lung and Serum. The left lung lobe and blood serum 
was frozen and shipped overnight to the Burke lab at UIUC on dry ice. The lung lobe was 
incubated for one hour at room temperature in collagenase (10 mg/mL in Kreb’s-Ringer buffer) 
at 1:1 (mg:µL) for each sample.3 The lungs were then mechanically homogenized in the 
eppendorf by plastic pestle. The homogenate was diluted with buffer (Kreb’s-Ringer, 4:1 w:v) 
and extracted with EtOAc (5 x 750 µL). The organic layers were combined and solvent removed 
in vacuo to give a dry residue. The residue was dissolved in DMSO (500 µL) and peridinin 
quantified by HPLC.  
 The serum was thawed and an aliquot (100 µL) was added to an eppendorf containing 
MeCN (500 µL). The sample was centrifuged (10,000 rpm x 5 min.), supernatant taken off and 
lyophilized to a powder. The residue was dissolved in DMSO (100 µL) and peridinin quantified 
by HPLC. 
 
Allergen Challenge Model. The OVA and HDM mouse models of acute asthma were 
performed in the laboratory of Xiaozhu Huang at the UCSF Sandler Asthma Basic Research 
Center as previously described.4, 5 Briefly, for the OVA model, mice were sensitized on days 0, 
7, and 14 by intraperitoneal (i.p.) injection of 50 µg OVA emulsified in 1 mg of aluminum 
potassium sulfate (alum). Control mice received an equal volume of alum only. On days 21, 22, 
and 23 mice were challenged once per day with intranasal delivery of 100 mg OVA in 40 µL 
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saline or saline alone. Twenty-four hours after the last OVA challenge the mice were sacrificed 
and the asthma phenotype and lipid peroxidation was analyzed. For the OVA model in which 
peridinin was applied, liposomal peridinin samples were prepared and mice were dosed by 
intranasal administration with either vehicle or 1 or 5 mg/kg peridinin once per day on days 20-
24 as described above. For the HDM model, mice were sensitized/challenged on days 0, 7, 14, 
and 21 by intranasal administration of 40 µL dust mite fecal pellet preparation (2.5 mg/mL; 
Greer Laboratories) or saline. Forty-eight hours after the last HDM sensitization/challenge the 
mice were sacrificed and the asthma phenotype and lipid peroxidation was analyzed. For the 
HDM model in which peridinin was applied, liposomal peridinin samples were prepared and 
mice were dosed by intranasal administration with either vehicle or 1 or 5 mg/kg peridinin once 
per day on days 14-16 and 21-23 as described above.  
 
Asthmatic Phenotype. Asthmatic response was characterized as previously described.4, 5 
Briefly, mice were attached to a pulmonary mechanics analyzer (FlexiVent, SCIREQ Inc, 
Canada), ventilated and paralyzed, and their airway mechanics were measured in response to 
acetylcholine administered in the tail vein. Serum samples were analyzed for OVA-specific IgE 
using an ELISA (BD Biosciences, clone R35-118). Total and differential cell counts were 
determined by hemocytometer and by light microscopic evaluation of more than 300 cells per 
slide. After lavage, lungs were inflated with 10% buffered formalin to 25!cm H2O and transferred 
to 10% buffered formalin. Sections (5 µm) were stained with H&E for semi-quantitative 
assessment of inflammation and PAS for evaluation of mucus production. To quantify 
inflammation, H&E-stained lung sections were de-identified for blinding and scored for 
peribronchial and perivascular inflammatory cell infiltration: grade 0, no infiltration; grade 1, 
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<25% of examined area; grade 2, 25–50%; grade 3, 51–75%; and grade 4, >75%. To quantify 
goblet cell hyperplasia, PAS stained lung sections were de-identified for blinding and scored for 
the percentage of PAS positive cells among airway epithelial cells: grade 0: none; grade 1 <25% 
of airway epithelial cells; grade 2, 25–50%; grade 3, 51–75%; and grade 4, >75%. 
 
Mouse Lung Homogenization. Each lung lobe was transferred to a 20 mL round-bottomed 
tube, massed, and placed on ice. To the tube was added 1 mL cold 0.1 M sodium phosphate 
buffer pH 7.4 containing 1 mM EDTA and 0.005% BHT per 100 mg tissue (i.e. for 80 mg lung 
sample, added 800 µL buffer). The sample was homogenized for 1 minute on ice at the highest 
speed utilizing a PowerGen 125 (Fisher Scientific) homogenizer. Between samples, the 
homogenizer was cleaned utilizing water and EtOH. The homogenate was transferred to a 15 mL 
conical tube and centrifuged (7800 rpm x 20 min.) at 4 °C to pellet the solids. The supernatant 
was aliquotted into clean eppendorf tubes, frozen in liquid N2, and stored at -80 °C.  
 
8-iso-PGF2α Sample Preparation. Mouse BALF sample was thawed and an aliquot (300 µL) 
was removed, frozen at -80 °C and lyophilized to a dry powder. This sample was then rehydrated 
with EIA buffer (300 µL) and 8-iso-PGF2α measured by 8-isoprostane ELISA kit (Cayman 
Chemical). An aliquot (50 µL) of mouse lung homogenate was frozen at -80 °C and lyophilized 
to a dry powder. The powder was rehydrated with EIA buffer (500 µL). An aliquot (100 µL) of 
this sample was diluted in EIA buffer (900 µL) and centrifuged (10,000 g x 10 min.). 8-iso-
PGF2α measured by 8-isoprostane ELISA kit (Cayman Chemical) in the supernatant. 
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8-iso-PGF2α Assay. Briefly, the 8-iso-PGF2α antiserum and acetylcholine esterase were thawed 
and dissolved in EIA buffer (30 mL). The 50 ng/mL 8-iso-PGF2α standard in EtOH was diluted 
9:1 in ultra pure water (Cayman Chemical) and standards were made at 500, 200, 80, 32, 12.8, 
5.1, 2.0 and 0.8 pg/mL and a second set of standards made at 350, 140, 56, 22.4, 9.0, 3.6 and 1.4 
pg/mL in EIA buffer. Onto the plate was loaded each standard (in duplicate) and each sample (5 
replicates each) in addition to the necessary control wells (blank (blk), B0, total absorbance (TA), 
non-specific binding (NSB)). To each well was added AChE tracer (50 µL/well) followed by 8-
iso-PGF2α antiserum (50 µL/well). The plate was covered by an adhesive plastic cover and 
incubated at 4 °C for 18 hours. The plate was then washed with the wash buffer (5 x 500 µL) and 
freshly prepared Ellman’s reagent (200 µL/well) was added to every well. AChE tracer (2 µL) 
was added to the TA well. The plate was incubated at room temperature in a plate-reader, 
shaking for the first 60 minutes and then absorbance was measured (412 nm) every 10 minutes 
while shaking for the next 60 minutes. The absorbance values used was the first reading in which 
the B0 wells averaged a raw absorbance value over 1 AU. The data was analyzed by subtracting 
the average of the blk wells from the absorbance value of every well. The %B/B0 was calculated 
for each well and the %B/B0 for the 15-point standard curve was fitted to a 4-parameter logistic 
curve (Origin Pro). This standard curve was used to calculate the concentration of 8-iso-PGF2α in 
each well. For the lung homogenate samples, protein concentration was determined by Pierce 
BCA Assay (Thermo Scientific) and utilized to normalize the concentration of 8-iso-PGF2α.  
 
MDA Assay.  
HPLC method. Isocratic 70:30 25 mM potassium phosphate buffer pH 6.5:MeOH, detect at 533 
nm, 1.75 mL/min, 100 µL injection, tR ~5.4 min.  
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BALF analysis. Eppendorfs containing BALF samples were thawed in a 37 °C water bath for 1 
minute. To 2 mL glass vials was added 15 µL 0.84% BHT in EtOH, 20 µL 4.88 M aq. 
phosphoric acid, 50 µL 0.5% aq. thiobarbituric acid (TBA) followed by 400 µL BALF. The 
BALF samples were immediately refrozen in liquid N2 and returned to -80 °C. Vials were 
capped with Teflon-lined caps, sealed with electrical tape, and heated at 90 °C for 45 minutes. 
After cooling, to each vial was added 100 µL of 1:11 (v/v) 5 M NaOH:MeOH and the sample 
vortexed to mix. Each vial was placed in a 15 mL conical to allow centrifugation (7500 rpm x 10 
min.). The supernatant was removed, filtered through a 0.2 µm filter into clean HPLC vials and 
analyzed by HPLC for MDA content.  
 
Lung homogenate analysis. Eppendorfs containing homogenate supernatant samples were 
thawed in a 37 °C water bath for 1 minute. To 2 mL glass vials was added 15 µL 0.84% BHT in 
EtOH, 150 µL 0.44 M aq. phosphoric acid, 50 µL 0.5% aq. TBA followed by 100 µL 
homogenate supernatant. The homogenate samples were immediately refrozen in liquid N2 and 
returned to -80 °C. Vials were capped with Teflon-lined caps, sealed with electrical tape, and 
heated at 90 °C for 45 minutes. After cooling, to each vial was added 300 µL of 1:11 (v/v) 1 M 
NaOH:MeOH and the sample vortexed to mix. Each vial was placed in a 15 mL conical to allow 
centrifugation (7500 rpm x 10 min.). The supernatant was removed, filtered through a 0.2 µm 
filter into clean HPLC vials and analyzed by HPLC for MDA content. Protein concentration in 
the homogenate samples was determined by Pierce BCA Assay (Thermo Scientific) and utilized 
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